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Chapter 1 
GENERAL INTRODUCTION 

1.1 IMMUNOGLOBULINS 
One of the activities of the immune system is the formation of 
antibodies. The proteins that exert antibody activity are called 
immunoglobulins. Immunoglobulin monomers have structural similarities 
as they all are composed of four polypeptide chains: two identical heavy 
chains and two identical light chains, linked together by inter- and intra-
chain disulphide bridges. The ultra-structural configuration of an 
immunoglobulin is Y-shaped (Figure 1.1). Both heavy and light chains 
consist of several domains. The variable domains (VH and VJ are 
situated at the N-terminal and form the antigen binding site. The 
constant domains (CH and CJ are situated on the C-terminal of the 
polypeptide chain (1). 
In humans five immunoglobulin classes named IgG, IgA, IgM, IgD 
and IgE can be distinguished. The distinction is made upon structural 
differences in the constant domains of the heavy polypeptide chains. 
C-terminal N- terminal 
Figure 1.1: Schematic representation of a monomeric IgA molecule. 
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1.2 IMMUNOGLOBULIN A (IgA) 
1.2.1 Structure, distribution and function of IgA 
The IgA monomer consists of two heavy (alpha) polypeptide chains and 
two light chains (kappa or lambda). IgA is a minor component of serum 
immunoglobulin (approximately 10-20%), but it is the most prevalent 
immunoglobulin on mucosal surfaces and in secretory fluids such as 
human milk, saliva, tears and secretions of the urogenital, respiratory 
and gastro-intestinal tract. Because of the abundance of IgA-secreting 
plasma cells in submucosal lymphoid aggregates, the total number of 
IgA molecules produced in humans is greater than that of any other 
immunoglobulin class (2). It has been estimated, for comparison, that in 
an adult the synthetic rates (mg of Ig/kg body weight/day) are 
approximately 66 for IgA, 34 for IgG, 7.9 for IgM, 0.4 for IgD and 0.02 
for IgE (3). 
Two IgA subclasses named IgA, and lgA2 can be recognized by 
small antigenic differences in the constant region of the alpha heavy 
chain. Differences between IgA, and IgA., in the hinge region (Figure 1.1) 
of the alpha chain lead to a different susceptibility to attack by 
proteolytic enzymes produced by several common bacterial species. Due 
to a deletion of a certain amino acid sequence in the hinge region of the 
alpha-2 chain, lgA2 is resistant to these enzymes (2). Circulating IgA 
consists of 90% IgA, and 10% lgA2, whereas the IgA subclasses are 
about equally distributed in secretions (1). 
Serum IgA is mainly found in the monomeric form and is produced 
by plasma cells located predominantly in the bone marrow and the 
spleen. Although serum IgA has antibody activity against a variety of 
antigens, the exact function of serum IgA in the immunological defense 
system remains unclear. IgA does not fix complement in the classical 
pathway, and it has been suggested that the role of serum IgA is to 
bind foreign antigens to large immune complexes that can be removed 
by the phagocytic system without inflammatory phenomena due to 
complement activation (4). 
The IgA found in secretions is largely dimeric, and is produced in 
plasma cells at local (submucosal) sites (1,2). Secretory IgA contains 
two extra chains: the J (joining or junction) chain and the secretory 
component (SC). The J chain is a 15,600 dalton polypeptide, produced 
by В lymphocytes, that binds two cysteine residues near the C-terminal 
of alpha chains and serves in the dimerization process of secretory IgA. 
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SC is a glycoprotein with, depending on the method of determination, a 
molecular weight of 50,000-90,000 dalton. It is produced in epithelial 
cells lining the mucosal surfaces (5-7). SC binds to IgA and serves in 
the transport of dimeric J chain-containing IgA into secretions. The 
resulting secretory IgA molecule is the predominant immunoglobulin in 
exocrine secretions and plays a primary role in mucosal immunity. 
Virtually all antigens presented to mucosal surfaces from the external 
environment stimulate the secretion of IgA antibodies. Secretory IgA 
forms complexes with antigens at the mucosal surfaces, thus preventing 
mucosal penetration of foreign antigens. The spectrum of activities is 
wide: it can neutralize viruses, bind toxins, agglutinate bacteria, inhibit 
bacteria from binding to cells, and bind to various food antigens (1,2,7). 
1.2.2 Ontogeny of IgA 
Compared to other immunoglobulins the development of IgA levels 
throughout life is slow. At birth, cord serum IgA concentrations have 
been estimated at 0.004 g/l (8). Unlike IgG, IgA cannot pass the 
placental barrier, so this IgA is likely to be of fetal origin. Serum IgA 
levels rise slowly during childhood, and adult values (1.4-2.6 g/l) are 
reached only at puberty (9). Maturation of the secretory IgA system is 
more rapid. Adult values of secretory IgA have been reported in saliva 
within two months after birth in an early study (10), but in a later study 
adult values for secretory IgA in stimulated saliva were attained at the 
age of 4-6 years (11). Distribution of plasma cells in the intestines is 
reported to be mature at the age of two years (12). 
1.2.3 IgA and breast-feeding 
Secretory IgA is also the predominant immunoglobulin in human milk. In 
fact, the observation that mother's milk contained an IgA that differed 
from serum IgA led to the first description of what was called to be 
secretory IgA (7). It has been recognized that breast milk antibodies 
were not absorbed, but functioned on the mucosal surfaces as a 
mucosal immunoglobulin in the gastro-intestinal tract of the infant. 
Secretory IgA is relatively stable, and a large part of milk IgA can be 
recovered from stool. Secretory IgA concentration can be very high in 
colostrum, but it comes down to a stable level of 50-75 mg/dl after the 
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first few weeks (7). The amount of secretory IgA delivered to a fully 
breast-fed infant is estimated to be at least 0.5 gram daily (100 mg 
secretory IgA/kg/day). Intestinal and bronchial antigen exposure of 
mothers can result in the appearance of secretory IgA antibodies in 
breast milk and other secretions, suggesting an entero-mammaric as 
well as a broncho-mammaric pathway of lymphoid cells that, after being 
primed with antigen, are involved in the homing process and are 
destined to become local immunoglobulin-secreting plasma cells (7). 
Numerous reports have been published stating the beneficial effects 
of breast feeding with its many defense factors (besides secretory IgA: 
lymphoid cells and other soluble factors as lactoferrin, enzymes and 
glycocompounds) upon prevention of infections and food allergy in the 
suckling infant. 
1.3 SELECTIVE IgA DEFICIENCY 
1.3.1 Definition of selective IgA deficiency 
Deficiency of serum IgA was first described in 1961 by Thieffry et al. in 
patients with ataxia telangiectasia (13). True cases of selective IgA 
deficiency were first described in 1962 by West et al. (14). 
Selective or isolated IgA deficiency was defined by Ammann and Hong 
in a restricted sense as a state with markedly diminished serum IgA 
levels (below 50 mg/l), normal levels of other immunoglobulins, normal 
antibody-mediated immunity and normal cell-mediated immunity (15). 
More recently the definition has been modified by not excluding a priori 
all patients with Τ cell abnormalities. Selective IgA deficiency now is 
defined as serum IgA levels below 50 mg/l, normal total levels of serum 
IgG and IgM, and no or at most mild abnormalities in Τ cell function 
(16). Patients with major immunodeficiency states as panhypogamma-
globulinemia, or clearly defined syndromes as ataxia telangiectasia are 
thus excluded. Some authors have introduced the term "partial" IgA 
deficiency for individuals with serum IgA levels above 50 mg/l but 
below -2SD of age-specific reference values (17). 
Serum IgA deficiency is almost invariably accompanied by 
deficiency of secretory IgA, although isolated deficiencies of either 
serum or secretory IgA have been described in some patients (16,18). 
Concomitant deficiencies of IgG subclasses, and/or IgD and/or IgE have 
been demonstrated in patients with "selective" IgA deficiency (19-23). 
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1.3.2 Frequency and genetics of IgA deficiency 
Selective IgA deficiency is the most common primary immunodeficiency 
in humans. The occurrence of selective IgA deficiency has been studied 
extensively in healthy individuals (mostly blood donors), and in 
numerous patient groups. In blood donors the frequency of selective IgA 
deficiency varies from 1:300 to 1:18,500 depending on the population 
and the chosen lower IgA limit for IgA deficiency (24-26). In patient 
groups elevated frequencies have been reported many times (25). In a 
survey of 486 healthy dutch school children four cases of selective IgA 
deficiency were found (1:122) (9). 
Most cases of IgA deficiency are sporadic, but familial occurrence 
has been reported. The patterns of inheritance are diverse. Autosomal 
dominant with or without variable expression, autosomal recessive, 
polygenic and multifactorial inheritance has been described (2,27-31). 
IgA heavy chain constant region genes (situated on chromosome 14) 
have been studied extensively in IgA deficient blood donors, but 
evidence for structural gene deletions could not be found (32). 
Associations between IgA deficiency and certain HLA antigens 
(especially B8 and DR3) have been shown (33). Aberrations of 
chromosome 18 and IgA deficiency were found in several cases (2,16). 
In families of individuals with hypogammaglobulinemia cases of IgA 
deficiency have been described, and in relatives of patients with 
selective IgA deficiency, aberrations in other immunoglobulins are not 
unusual (29,30,34). 
1.3.3 Anti-lgA antibodies 
An important feature in patients with selective IgA deficiency is the 
development of anti-lgA antibodies, reported in frequencies up to 40% 
(16). The reason why a substantial number of IgA deficient individuals 
develop anti-lgA antibodies and others do not is not clear. 
In individual cases development of anti-lgA after transfusion with IgA 
containing products (blood or gamma-globulin) is well-known, but such a 
causal relation could not be recognized in large studies. It has been 
suggested that development of anti-lgA antibodies may be the result of 
an increased absorption of antigenic substances that are cross-reactive 
with IgA, analogously to the development of blood group isoagglutinins. 
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Data upon the question at what age anti-lgA antibodies become manifest 
are very scarce in the literature. 
Anti-lgA antibodies can be class-specific or of limited specificity, for 
instance only directed against IgA, or ІдА
г
. Anti-lgA is mostly of the IgG 
class, but IgE antibodies to IgA have been described (35). The clinical 
importance of presence of anti-lgA antibodies lies in the fact that they 
may result in hazardous reactions after transfusion of IgA-containing 
products (36). 
The role of anti-lgA antibodies in the pathogenesis and/or 
maintenance of IgA deficiency is not known. In vitro studies have 
revealed that anti-lgA, when added to cell cultures, inhibits in vitro IgA 
synthesis (37,38). However, as most IgA deficient individuals lack anti-
lgA antibodies, this in vitro phenomenon is not likely to play an 
important role. Interesting observations have been reported in mothers 
with IgA deficiency and circulating anti-lgA antibodies, suggesting that 
transplacental passage of anti-lgA antibodies of the IgG class may result 
in IgA deficiency in the progeny, although the underlying mechanism 
remained obscure (39,40). 
1.3.4 Acquired and transient IgA deficiency 
IgA deficiency is not always a primary immunodeficiency, but can also 
develop during treatment with various drugs. Diminished serum IgA 
levels have been reported in connection with anticonvulsants 
(Phenytoin), and slow-acting antirheumatic drugs (penicillamin, 
sulfasalazine and gold salts) (41-47). Most drug-induced IgA deficiencies 
are temporary, or reversible after withdrawal of the drug, although 
persistent IgA deficiency has been reported (44-47). 
Normalization of serum IgA levels in formerly IgA deficient 
individuals has been described on several occasions and has been 
termed transient IgA deficiency (48). Generally this phenomenon is found 
in young children, and merely reflects delayed maturation of the IgA 
system. For this reason it seems appropriate to keep some reserve in 
diagnosing selective IgA deficiency under the age of one year. 
Especially among cases of "partial" IgA deficiency normalization of IgA 
levels is common (17). 
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1.4 CLINICAL MANIFESTATIONS IN SELECTIVE IgA DEFICIENCY 
1.4.1 General remarks 
The clinical manifestations of IgA deficiency are heterogeneous. Most IgA 
deficient individuals found in community-based studies appeared to be 
healthy. On the other hand, associations with a variety of diseases 
including auto-immune disorders, recurrent infections, gastro-intestinal 
disease and allergic disorders have been described many times (16,49-
52). However, associations between selective IgA deficiency and clinical 
symptoms as outlined below should be considered with some caution, 
as in most reports patient groups mainly consisted of selected 
populations, either biased by positive selection as a (healthy) blood 
donor or negatively biased as a referred patient in hospital-based series 
(25). Surveys of somewhat unselected patients are scarce, but usually 
reveal no striking associations between selective IgA deficiency and 
disease (25). 
Symptomatic patients with selective IgA deficiency have in common 
that clinical manifestations mostly can be related to the absence of IgA 
in the secretions. Secretory IgA is the major immunoglobulin in 
secretions, acting in the protection of mucosal surfaces against invading 
micro-organisms and preventing penetration of toxins and allergens. So 
absence of IgA can facilitate infections involving the mucous membranes 
of the upper and/or lower respiratory tract, or of the gastro-intestinal 
tract. It is also conceivable that the elevated absorption of foreign 
antigens may result in an increased incidence of allergic and auto-
immune diseases. Since secretory IgA is so clearly thought to be an 
important part of the local mucosal immune system, it is still unclear why 
the majority of individuals with selective IgA deficiency are reported to 
have no complaints whatsoever. Generally this is attributed to 
compensatory mechanisms in other areas of the immune system, for 
instance substitution of other immunoglobulin classes for IgA in 
secretions (16). 
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1.4.2 Recurrent Infections and its association with concomitant 
IgG subclass deficiencies 
The majority of symptomatic IgA deficient patients suffer from frequent 
infections, mainly of the respiratory tract including middle ear and 
paranasal sinuses (16,49-52). Infections are mostly mild to moderately 
severe. The incidence of severe life-threatening infections is not 
increased in patients with selective IgA deficiency. 
Concomitant deficiency of IgG subclasses in individuals with 
"selective" IgA deficiency was first reported by Oxelius et al. (19), and 
was found to predispose to more serious and more frequent (respiratory 
tract) Infections. Thereafter this finding has been confirmed in numerous 
other studies. Björkander et al. reported bronchiectasles and impaired 
lung function in combined IgG subclass-lgA deficiency (53). IgG 
subclass deficiency associated with IgA deficiency mainly refers to lgG2 
deficiency and to a lesser extent lgG4 deficiency. Combined lgA-lgG2-
lgG4 deficiency is not uncommon. Since antibody activity against 
polysaccharide antigens resides predominantly within the lgG2 subclass 
(54,55), this explains the increased rate of sinopulmonary infections with 
polysaccharide capsulated bacteria as Haemophilus influenzae and 
Streptococcus pneumoniae. The clinical relevance of concomitant lgG4 
deficiency remains debatable. Due to the very broad spread in 
childhood, reference values for lgG4 are not available, and up to 8% of 
healthy children have no detectable lgG4 (56). It is thought that recurrent 
infections in individuals with lgG4 deficiency are more likely to be 
associated with coexisting IgA and/or lgG2 deficiency (57). 
1.4.3 Gastro-Intestinal diseases 
Chronic infections of the gastro-intestinal tract are rare in selective IgA 
deficiency (58), suggesting that compensatory mechanisms could be 
operating in the intestine (59). 
Reports of other gastro-intestinal disorders associated with selective 
IgA deficiency are various. They include pernicious anemia (60), 
ulcerative colitis (61), Crohn's disease (61), giardiasis (62), and nodular 
lymphoid hyperplasia (63). Among patients with coeliac disease 
increased frequencies of IgA deficiency have been reported (58,64). The 
response to gluten-free diet usually Is good, and comparable to that of 
individuals who are not IgA deficient. 
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Antl-bovidae antibodies of the IgG class are often found in serum of 
IgA deficient individuals (64). Cow's milk precipitins have been reported 
in frequencies up to 75% (65), and can lead to the formation of 
(possibly harmful) circulating immune complexes (66). 
1.4.4 Allergy 
Allergic diseases are more often found in IgA deficient individuals 
(24,65). The most common allergic diseases established include allergic 
rhinitis, atopic eczema, bronchial asthma and urticaria. Allergic diseases 
in selective IgA deficiency appear to have a more chronic course and 
are less associated with seasonal influences (16). Treatment can be 
more difficult because of a greater incidence of respiratory tract 
infections. 
1.4.5 Auto-Immune disorders 
The auto-immune diseases most commonly associated with IgA 
deficiency are rheumatoid arthritis and systemic lupus erythematosus 
(16,50,67). Other with auto-immunity related disorders reported in 
patients with selective IgA deficiency include pernicious anemia (60), 
ulcerative colitis (61), Crohn's disease (61), dermatomyositis (61), 
pulmonary haemosiderosis (64), thyreoiditis (68), chronic aggressive 
hepatitis (69), Addison's disease (70), Sjögren syndrome (71) and 
idiopathic thrombocytopenic purpura (71). Presence of auto-antibodies 
(without manifest disease) against parietal cells, basement membrane, 
mitochondria, DNA, thyroglobulin, collagen and smooth muscle have 
been reported in IgA deficient individuals (64,72-74). 
Buckley found relatively low frequencies of auto-immune disorders 
in children with selective IgA deficiency (29). However, in adults 
associations with auto-immune disorders are thought to be sufficiently 
frequent to warrant periodic investigation for auto-immunity in all IgA 
deficient patients (16). 
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1.5 PATHOGENESIS OF IgA DEFICIENCY 
1.5.1 Introduction 
Most investigators agree upon a developmental defect in В cell 
maturation towards IgA-producing plasma cells as the major cause of 
selective IgA deficiency. The cellular and molecular mechanisms involved 
in the regulation of lymphoid cells to differentiate towards IgA-producing 
plasma cells and in the control of their characteristic distribution in 
mucosal tissues are only partially understood (3). IgA plasma cells 
represent the endpoint of isotype-specific В cell differentiation. This 
process is influenced at various stages by Τ cells and/or Τ cell-derived 
cytokines (Figure 1.2). IgA production and secretion into serum and 
secretory fluids are the net result of a complex network of interacting 
cells. Most investigations on this matter have been done in the murine 
system, and application of the results to humans has to be done with 
some caution (3,75). Mature В cells (slgD\slgM+) switch to surface IgA 
positive (slgA+) cells either by direct or successive pathways (3). This 
process is thought to be influenced by Τ switch cells, environmental 
antigens and/or interleukin (IL)-4 (3,76). IL-5 induces activated slgA* В 
cells towards proliferation and clonal expansion (3,76,77). Finally, IL-6 
(and perhaps IL-5) induces differentiation of slgA+ В cells into IgA-
secreting plasma cells (78). 
In several studies however, the number of slgA* В cells in 
peripheral blood in IgA deficient individuals was found to be normal (79-
81). In contrast to these findings Conley and Cooper reported decreased 
numbers of slgA* cells (82). The slgA* cells in their study were not only 
decreased in number, but also stained for slgM and slgD, indicating an 
immature state of differentiation (Figure 1.2). Compared to normal 
individuals the number of these slgA*-slgD*-slgM+ cells was increased. It 
was suggested that В cell maturation in selective IgA deficiency is 
arrested in a very early stage of differentiation (82). Decreased numbers 
of slgA* cells have also been reported by others (83-85), but in these 
studies В cells were not investigated with double-staining techniques. 
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Figure 1.2: Regulation of В cell differentiation from lymphoid stem cell to IgA-
producing plasma cell. The figure is limited to the IgA В cell lineage. 
The stages at which Τ cells directly influence the differentiation pathway 
are not fully known. 
1.5.2 In vitro studies 
In many in vitro studies the capacity of peripheral blood mononuclear 
cells (PBMC) from IgA deficient patients to differentiate into IgA-
producing plasma cells has been investigated. In an early report 
pokeweed mitogen (PWM)-driven cell cultures resulted in normal 
amounts of IgA-containing plasma cells and normal IgA secretion (86). 
Waldmann et al. reported a secretory blockade in IgA-producing plasma 
cells (87). However, in most other in vitro studies PBMC of IgA deficient 
individuals were unable to produce IgA (81,83-85,88-92). 
The cellular basis underlying selective IgA deficiency has been 
investigated in many studies (80-92). Most studies were limited to small 
numbers of patients, and populations were not always well-defined with 
regard to age, mode of inheritance and clinical manifestations. 
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Interpretation and comparison of the results is hampered by the fact that 
often different methods were used. In early reports PBMC of IgA 
deficient individuals and controls were mixed and cultured together in 
PWM-driven cell cultures. PBMC of some patients were found to depress 
IgA production by PBMC of controls, but the nature of this suppressive 
activity became not clear (87-89). In later studies PBMC of IgA deficient 
Individuals and of healthy controls were separated into non-T and Τ cell 
fractions (81,83-85,90-92). The non-T and Τ cell fractions of IgA deficient 
individuals were cocultured with counterpart cell fractions of controls, 
thus enabling the separate investigation of В and Τ cell functions. It was 
recognized that in some patients with selective IgA deficiency Τ cell 
regulatory disturbances existed (90,91). In efforts made to distinguish Τ 
helper and suppressor activity different methods have been used: 
irradiation of the Τ cell fraction (81,85), depletion of CD4* or CD8+ cells 
by complement-mediated lysis (81,84), addition of hydrocortison 
(84,90,91) or treatment with mitomycin С (92). The coculture studies that 
enabled appropriate distinction between В and Τ cell functions and that 
were methodically comparable showed heterogeneous results (Table 
1.1). So, the cellular basis of selective IgA deficiency has often been 
found to be a pure arrest in В cell maturation, but excessive Τ 
suppressor function, diminished Τ helper function, and combinations of 
В and Τ cell abnormalities have also been reported. 
Table 1.1: Results of comparable coculture studies investigating the cellular basis of 
selective IgA deficiency. 
numbers of patients 
Study 
Oen et al. 
Cassidy et al. 
Klemola et al. 
Inoue et al. 
Shinomya et al. 
(Ref) 
(81) 
(83) 
(84) 
(85) 
(92) 
В 
12 
8 
19 
5 
5 
В = defective В cell function 
Ts = excessive Τ suppressor function 
Th = diminished Τ helper function 
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1.6 AIM OF THE STUDY 
In the past decades much has already been written about selective IgA 
deficiency. There have been numerous reports on frequencies of 
selective IgA deficiency in all kinds of populations, on modes of 
inheritance, on clinical manifestations, on pathogenic mechanisms, and 
on associations with other immune disturbances. Although it is generally 
considered to be the most frequent primary immunodeficiency, the 
results of studies on the different aspects of selective IgA deficiency are 
rather heterogeneous. Up to the present there is no good explanation 
for this heterogeneity. However, most reports shared in common that the 
populations or patient groups studied were also heterogeneous or 
biased. In many studies the analysis of results did not take into account 
differences in sex, mode of inheritance, or presence or absence of 
clinical manifestations, and selective IgA deficiency was not always well-
defined. Only a few studies have reported longitudinal data 
(17,29,48,93), whereas the majority represented cross-sectional studies. 
Investigations on pathogenesis were mostly limited to small numbers of 
patients and different methods were used. In our opinion these 
considerations could explain at least some part of the heterogeneity of 
selective IgA deficiency in the literature. 
In this thesis an effort was made to investigate the different aspects 
of selective IgA deficiency in a well-defined and longitudinally 
documented group of children and adolescents. In the past fifteen years 
selective IgA deficiency has been diagnosed in a large group of children 
known to the Department of Pediatrics of the University Hospital 
Nijmegen. The majority was diagnosed after referral for complaints as 
recurrent infections or atopic diseases. Four children were diagnosed in 
the "Nijmegen Growth Study" (9). Family screening for IgA deficiency 
revealed additional cases in 8 families, and allowed formation of two 
groups: "sporadic" and "familial" IgA deficiency. Most patients have 
been carefully followed during regular outpatient visits. The main goal of 
our studies was to investigate whether division of the patients into 
"sporadic" and "familial" cases could lessen the well-known heterogeneity 
of IgA deficient individuals with regard to clinical manifestations as well 
as to the underlying pathogenic mechanism responsible for selective IgA 
deficiency. 
25 
1.7 OUTLINE OF THE THESIS 
The longitudinal clinical manifestations in 25 cases of "sporadic" and 15 
cases of "familial" IgA deficiency are described in Chapter 2. 
In order to investigate the cellular basis of IgA deficiency a system 
for PWM-driven in vitro immunoglobulin production was made 
operational. Using coculture techniques with counterpart non-T and Τ 
lymphocytes from healthy controls, and applying adapted statistical 
comparisons it was possible to distinguish defective В cell function, 
excessive Τ suppressor function and diminished Τ helper function. The 
methods and statistical calculations of the cell culture system are 
described in Chapter 3. 
In vitro immunoglobulin production was studied in 22 patients 
without anti-lgA antibodies, including both "sporadic" and "familial" 
cases. The results of the in vitro experiments were compared to the 
clinical manifestations (Chapter 4). 
The cell culture system was used to investigate the capacity for in 
vitro immunoglobulin production in four IgA deficient children of two IgA 
deficient mothers with class-specific anti-lgA antibodies. Three of these 
children had anti-lgA antibodies themselves. The results of the 
experiments and the implications on pathogenesis of IgA deficiency in 
this apparently distinct group of patients are described in Chapter 5. 
The cell culture system was also used to investigate in vitro 
Immunoglobulin production in three patients with juvenile chronic arthritis 
who, while treated with aurothioglucose, developed markedly diminished 
IgA levels (Chapter 6). 
During the follow-up period the serum IgA levels in the patients 
were measured with a sensitive technique. In Chapter 7 the longitudinal 
course of serum IgA and other immunoglobulin levels are described. 
In Chapter 8 the results and conclusions of the investigations are 
discussed. 
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Chapter 2 
CLINICAL MANIFESTATIONS IN SELECTIVE IgA DEFICIENCY IN 
CHILDHOOD 
A Follow-up Report 
P.C.J, de Laat, C.M.R. Weemaes, R. Gonera, P.J.J, van Munster, 
J.A.J.M. Bakkeren, G.В.A Stoelinga. 
Department of Pediatrics 
University Hospital Nijmegen 
The Netherlands 
Acta Paediatrica Scandinavica 1991;80:798-804 
2.1 ABSTRACT 
Clinical manifestations ¡η 40 children with selective IgA deficiency were 
studied during a follow-up period of 2-10 years. The patients were 
divided into two groups: group I consisted of 25 children with "sporadic" 
IgA deficiency and group II of 15 children with "familial" IgA deficiency. 
Respiratory tract infections including otitis media were frequent in both 
groups. Concomitant lgG2-lgG4 deficiency was found in two patients in 
group I. Longitudinal serum IgG levels were elevated significantly in both 
groups. Atopic complaints were observed in 10 children of the "sporadic" 
group, but only in two of the "familial" group. However, elevated serum 
IgE levels were more often found in group II. Two children of group I 
were mentally retarded and chromosomal examination showed abnormal­
ities in both. Anti-lgA antibodies were detected in one child in group I 
and three children in group II. These three patients had an IgA deficient 
mother with class-specific anti-lgA antibodies. Concomitant lgG4-lgE 
deficiency was found in all four. 
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2.2 INTRODUCTION 
Selective IgA deficiency is generally considered to be the most common 
primary immunodeficiency in man, occurring in frequencies varying from 
1:300 to 1:3000, depending on screened population and the applied 
definition (1,2). The clinical relevance of selective IgA deficiency is 
controversial. It can be found in healthy individuals (e.g. blood donors), 
but otherwise there are many reports describing an association between 
selective IgA deficiency and disease, especially recurrent infections, 
auto-immune disorders, atopic disease and gastro-intestinal diseases (3-
5). Simultaneous deficiency of IgA and one or more IgG subclasses has 
been described, and appears to predispose to more severe and more 
frequent infections (6,7). 
In most cases selective IgA deficiency occurs sporadically, but 
familial occurrence with autosomal dominant, autosomal recessive or 
polygenic patterns of inheritance has been reported (2,3). 
The aim of our study was to look for possible differences in clinical 
manifestations between "sporadic" and "familial" cases of selective IgA 
deficiency, and in this way to try to find an explanation for the well-
known heterogeneity observed in IgA deficient individuals. 
2.3 PATIENTS AND METHODS 
2.3.1 Patients 
During a 10-year period selective IgA deficiency was diagnosed in 40 
children. Selective IgA deficiency was defined according to Hong & 
Ammann (8). They include those patients with markedly diminished 
serum IgA levels (<0.05 g/l), normal total levels of serum IgG and IgM, 
and no or at most mild abnormalities of Τ cell function. Diagnosis was 
only made after the age of one year. Patients with ataxia telangiectasia 
were excluded from this study. None of our patients used Phenytoin, 
penicillamin or sulfasalazine, agents with known ability to induce 
secondary IgA deficiency (9-11). 
The patients were divided into two groups. Group I consisted of 25 
children who, as family studies revealed no other cases of IgA 
deficiency, were designated as "sporadic" cases (Table 2.1). Two 
children were mentally retarded and chromosomal examination showed 
abnormalities: a boy (P.M.) with ring-chromosome 22 without further 
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complaints, and a girl (E.vdB.) with ring-chromosome 18 who was 
suffering from chronic aggressive hepatitis and died at the age of seven. 
Four children were diagnosed in the "Nijmegen Growth Study" (12). 
Group II consisted of 15 children with "familial" IgA deficiency who all 
had a sib with selective IgA deficiency (Table 2.2). The sibling of one of 
our patrents was excluded from this study because of insufficient follow-
up. Four children belonging to two families had a mother with IgA 
deficiency and class-specific anti-lgA antibodies. One of them (Y.T.) 
developed normal serum IgA levels during his first year of life (13), but 
at re-examination at the age of five was found to be IgA deficient. 
Out-patient follow-up visits took place at least 2-3 times yearly for a 
period of 2 to 10 years; serum immunoglobulin levels were measured, 
and clinical information was carefully recorded. Recurrent infection was 
defined according to Plebani et al. (5) as the occurrence of at least 
seven episodes of infection in one year of follow-up; or five or more 
episodes in each of two years of follow-up, or three or more episodes in 
each of 3 or more years of follow-up. Allergic rhinitis, asthma or atopic 
eczema were classified as atopic disease. 
2.3.2 Serum immunoglobulin measurements 
IgG, IgA and IgM levels were determined by single radial immuno-
diffusion modified by Van Munster et al. (14) till 1979, and later by laser-
nephelometry. All values were calibrated against WHO standard serum 
No. 67/97. Class-specific anti-lgA antibodies were determined by a 
titration-radioimmunoassay as previously described (15). IgG subclass 
levels were determined by radial immunodiffusion (14) and calibrated 
against standard serum containing IgG, 6.2 g/l; lgG2 2.4 g/l; lgG3 0.64 g/l 
and lgG4 0.46 g/l (HOO-020, The Central Laboratory of the Netherlands 
Red Cross Blood Transfusion Service). IgG, < 3.1 g/l, IgG-, < 0.48 g/l at 
the age of 2-5 years and < 0.72 g/l afterwards, and IgGa < 0.16 g/l {P3 
values according to a recent study of Plebani et al. (16)) were 
considered as an indication of deficiency of the respective IgG subclass. 
IgG, levels below 0.046 g/l were considered as an indication of lgG4 
deficiency. 
IgE levels were determined by a radioimmunoassay. Lowest limit of 
detection was 12 ug/l (5 lU/ml). Undetectable values were considered as 
an indication of IgE deficiency. Serum IgE levels in our patients were 
compared with those provided by Kjellman (17). Values above +1 SD 
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were designated "high". In Kjellman's study IgE levels above +1 SD were 
correlated with an increased incidence of atopic complaints (17). 
2.3.3 Statistical analysis 
The IgG and IgM levels of the patients were compared with the 
population growth standards obtained in the "Nijmegen Growth Study" 
(12). Only children with at least two measurements between 3.5 and 14.5 
years of age were admitted. In case of related children only one of them 
was randomly chosen for analysis. 
Assuming log normal distribution for IgG and IgM levels and 
making use of age and sex adjusted means and standard deviations of 
the healthy population, for each child the average ζ of the standardized 
values of the logarithmically transformed measurements was determined. 
For testing the null hypothesis that the IgG and IgM levels of IgA 
deficient children do not deviate from those of normal children, 
approximate chi square tests were applied; the number of children as 
the number of degrees of freedom and the sum of the squared values z2 
as the test statistic. 
2.4 RESULTS 
2.4.1 Clinical findings 
Infections: In both groups the main clinical manifestations at 
diagnosis and during follow-up were recurrent respiratory tract infections 
(Tables 2.1 and 2.2). Recurrent otitis media was observed in 12 children 
of group I and in 8 children of group II. Implantation of Fowler drains 
was performed in half of the cases. Mostly the infections tended to 
become milder during the follow-up period. Severe infections were rare 
at diagnosis and during follow-up. The two children with recurrent 
urinary tract infections (E.D. and Ba.B.) had vesico-ureteric reflux. From 
the 12 children found to be selectively IgA deficient in family studies or 
in the "Nijmegen Growth Study" 9 were asymptomatic at diagnosis. Only 
4 of them remained asymptomatic during the entire follow-up period. The 
others all developed complaints during follow-up, mainly consisting of 
recurrent otitis media. 
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Atopie diseases: Atopie complaints were also frequently found 
(Tables 2.1 and 2.2). The incidence was higher in the "sporadic" group: 
10 children with atopic manifestations in group I versus 2 In group II. 
Severe forms of asthma or atopic eczema did not occur. 
Gastrointestinal problems: Gastrointestinal complaints were 
reported in several patients of both groups. Two children of group II had 
coeliac disease at diagnosis of selective IgA deficiency. Both responded 
well to a gluten-free diet. In patient M.M. a normal diet was reinstituted 
after two years without recurrence of coeliac disease. One patient 
developed Crohn's disease at the age of twenty. Another patient 
developed bloody stools due to lymphofollicular hyperplasia at the age 
of seventeen. 
2.4.2 Immunological findings 
In most patients studied longitudinal serum IgG levels (follow-up period: 
2-10 years) were significantly elevated (p < 0.001) compared to our age 
and sex specific normal values (12). Serum IgM levels were within, or 
slightly above, the normal range (p = 0.19). Between the "familial" and 
"sporadic" group no differences were observed in serum IgG and IgM 
levels. IgG subclass levels were determined in 36 patients and in some 
children concomitant IgG subclass deficiencies were found. Combined 
lgG2-lgA deficiency was not observed in our patients. Combined lgG4-lgA 
deficiency was observed in eight patients; four in each group. Two of 
them (in group II) suffered from recurrent lower respiratory tract 
infections, and 5 children (3 in group I; 2 in group II) had recurrent otitis 
media. The clinical relevance of the lgG4 deficiency found In 20% of our 
patients is debatable. Due to the very broad spread in childhood, lgG4 
reference values are not available, and lgG4 deficiency is difficult to 
define (16). 
lgG2-lgG4-lgA deficiency was found in two boys. One boy was 
mentally retarded and had a ring chromosome 22; he had neither 
recurrent infections nor atopic disease. The other boy suffered from a 
Haemophilus influenzae meningitis and severe respiratory tract infecti-
ons. During follow-up his IgG and IgM levels declined too, and antibody 
responses were impaired or negative. He must be regarded as a case of 
late-onset hypogammaglobulinemia. 
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Table 2.1: Clinical manifestations In group I: 25 children with "sporadic" IgA deficiency. 
- = no complaints. UTI = urinary tract infections. RA = rheumatoid arthritis. 
Recurrent infections: В = bronchitis, О = otitis, OF = otitis with Fowler drains. 
Atopic diseases: A = asthma, E = atopic eczema, R = allergic rhinitis. 
Patient 
B.S. 
R.vdB. 
D.G. 
C.W. 
E.D. 
I.A. 
H.B. 
E.vdB. 
P.dG. 
T.B. 
D.J. 
Tj.J. 
J.A. 
M.vdB. 
B.K. 
M.dK. 
P.M. 
V.P. 
C E . 
S.vB. 
C S . 
W.L. 
M.C. 
R.vW. 
P.N. 
Age (yr) 
at diag. 
1 
1 
2 
2 
2 
3 
3 
3 
4 
5 
7 
8 
8 
8 
9 
9 
9 
10 
11 
11 
13 
13 
14 
16 
16 
Sex 
F 
M 
F 
F 
M 
F 
M 
F 
M 
M 
M 
M 
M 
M 
F 
M 
M 
F 
F 
M 
F 
M 
F 
F 
M 
Complaints 
At diagnosis 
A E 
В 
Lymphadenitis 
Diarrhoea, О 
UTI, OF 
0 
Β A E 
During follow-
0-2 yr 
A E 
OF 
В OF 
OF A 
OF 
0 
A E 
up period 
Retardation, Chronic aggressive 
Fever e.c.i. 
OF A E 
В 
В О 
А E 
В 
Constipation 
В 
Retardation, 
Pneumonia 
RA? 
-
A 
R 
-
Hypomagn.,0 
0 
Meningitis.B 0 
0 
OF A E 
Osteomyelitis 
-
0 A E R 
-
OF 
В 
-
-
-
A 
R 
R 
-
-
В 0 
,R 
2-5 yr 
A E 
OF 
OF 
-
OF 
0 R 
-
hepatitis 
0 
A R 
0 R 
-
-
-
В 
— 
-
-
A 
R 
R 
-
-
В 
5-10 yr 
A E 
OF 
-
0 
-
R 
-
A 
O A R 
Bloody stools 
-
-
В 
— 
A 
M.Crohn, R 
-
Table 2.2: Clinical manifestations in group II: 15 children with "familial' IgA deficiency. 
- = no complaints. UTI = urinary tract infections. 
Recurrent infections: В = bronchitis, О = otitis, OF = otitis with Fowler drains. 
Atopic diseases: A = asthma, E = atopic eczema, R = allergic rhinitis. 
Patient 
R.F. 
D.F. 
Ba.B. 
Bu.B. 
T.M. 
M.M. 
B.O. 
N.T. 
Y.T. 
W.L. 
A.L. 
P.D. 
M.D. 
M.J. 
T.J. 
Age 
at d 
3 
2 
2 
2 
1 
3 
2 
1 
5 
6 
4 
5 
7 
7 
6 
(yr) 
iag. Sex 
M 
M 
M 
F 
M 
M 
M 
M 
M 
F 
F 
F 
F 
M 
M 
Complaints 
At diagnosis 
Arthralgia 
-
UTI 
-
-
Coeliac disease 
В 
-
-
В 
-
Coeliac disease 
Β E 
Bloody stools 
— 
During 
0-2 yr 
0 
0 
-
OF 
0 
В 0 
B O A 
OF 
-
В 
-
follow-up period 
2-5 yr 
0 
-
OF 
-
-
В A 
OF 
-
В 
-
Persistent coeliac disease 
В OF E 
Bloody 
— 
stools 
В OF E 
-
— 
5-10 yr 
-
-
-
-
-
OF 
В 
-
В OF E 
-
— 
Table 2.3: Numbers of patients with atopic manifestations in relation to the serum IgE 
levels observed. Serum IgE levels were designated "normal" or "high" accor­
ding to Kjellman (17). Values below 5 lU/ml were considered as an indication 
of IgE deficiency. 
Group I 
("sporadic") 
Group II 
("familial') 
Serum IgE levels Deficient Normal High 
Number of patients 
Total 8 12 5 
Atopic complaints 3 3 4 
Deficient Normal High 
4 
0 
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High levels of serum IgE were more often found in group II (Table 
2.3). Only two of the six children with "familial" IgA deficiency and high 
IgE levels suffered from atopic complaints. In the "sporadic" patients 
high serum IgE levels corresponded better with the occurrence of atopic 
disease. Surprisingly, 3 children in group I with concomitant IgE 
deficiency suffered from allergic rhinitis. Their serum IgG, levels were 
normal. 
During the follow-up period 4 boys (2 in group I; 2 in group II) 
developed serum IgA levels above 50 mg/l. Although there was 
considerable variance during the follow-up period and serum IgA levels 
are still very low compared to normal values, these patients no longer 
meet the definition of selective IgA deficiency, and could represent 
cases of transient IgA deficiency. Noteworthy is the fact that HB has an 
identical twin brother who is not IgA deficient. 
In 4 of the 36 children who remained IgA deficient during the follow-
up period, development of class-specific anti-lgA antibodies was 
detected. None of them had received a transfusion with IgA-containing 
products. Three of these children had a mother with IgA deficiency and 
anti-lgA antibodies; they developed anti-lgA antibodies at the ages of 
three, seven and nine, respectively. The fourth patient was a girl in the 
"sporadic" group referred to our clinic because of convulsions due to 
hypomagnesemia caused by an excessive renal loss of magnesium. Anti-
lgA antibodies in her case were first detected at the age of eighteen. 
Besides recurrent otitis media she had no other complaints. In all four 
patients who developed anti-lgA antibodies a concomitant lgG4-lgE 
deficiency was detected. 
2.5 DISCUSSION 
In both groups of children with selective IgA deficiency clinical 
manifestations appeared to be similar. They mainly consisted of mild 
respiratory tract infections including recurrent otitis media. The 
occurrence of recurrent otitis observed in our study was impressive, and 
as high as the 44% incidence reported by Buckley (3). 
Associations between selective IgA deficiency and clinical symptoms 
should be considered with some caution, as in most reports and in this 
study too, patient groups mainly consist of children referred for 
complaints, and are possibly not representative for the total IgA deficient 
population (18). However, of the twelve children who were not referred 
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for complaints, the majority also had respiratory tract infections during 
the follow-up period. In our opinion this finding ¡s a reliable indication of 
the predominance of recurrent respiratory tract infections in children with 
selective IgA deficiency. Although recurrent infections were more 
frequently found in the younger patients (Tables 2.1 and 2.2), follow-up 
studies revealed that they also occurred at older ages in the children of 
both groups. 
Analysis of longitudinal serum immunoglobulin levels in our patients 
revealed a statistically significant elevation of IgG in both groups. We 
think this elevation is caused by the high incidence of infections, and in 
this way also supports the predominance of recurrent infections in 
children with selective IgA deficiency proposed above. Combined 
deficiencies of IgG subclasses and IgA were not frequent in our patients. 
In group I two boys with lgG2-lgG4-lgA-lgE deficiency were found. One 
boy surprisingly had no complaints whatsoever. The other boy, suffering 
from severe recurrent infections, developed late-onset hypogam-
maglobulinemia, and resembles the patient described by Morell et al. 
(7). Selective IgA deficiency is thought to be a condition that 
predisposes to atopic disease (4). We found a high incidence of atopic 
complaints in group I, but not in Group II. The difference in occurrence 
of atopic complaints observed between both groups may be due to the 
fact that most of the patients in group I were referred because of 
complaints, whereas half of the patients in group II were not referred. 
However, only five children of group I were referred for atopic 
complaints. One atopic patient was found in the "Nijmegen Growth 
Study" (CS), and in four children of group I atopic complaints became 
manifest during follow-up. Perhaps patients with "sporadic" IgA 
deficiency are more prone to develop atopic complaints. No association 
could be established between height of serum IgE levels and the 
incidence of atopic complaints. In group II the incidence of atopic 
complaints was low despite high serum IgE levels. In group I three 
children with normal serum IgE levels had asthma and/or eczema, and 
three children with IgE deficiency even suffered from allergic rhinitis. 
Four boys showed a rise in serum IgA levels above 50 mg/l and we 
think they represent cases of transient IgA deficiency. Two of them were 
asthmatic (Table 2.1), and dyspnoeic attacks became less frequent. 
Patient DF was asymptomatic at diagnosis (Table 2.2), but later 
developed recurrent otitis despite the rise in serum IgA. 
Chromosomal abnormalities in selective IgA deficiency with 
emphasis on chromosome 18 (deletion, ring formation) have been 
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reported earlier (4). In our patients chromosomal analysis was performed 
in sixteen children (19). In two of them chromosomal abnormalities (ring 
22 and ring 18) were found, and both children were mentally retarded. 
In mentally retarded children with selective IgA deficiency chromosomal 
analysis is strongly recommended. 
In four children class-specific anti-lgA antibodies were 
demonstrated. Three of them had an IgA deficient mother with anti-lgA 
antibodies. The possibility of induction of selective IgA deficiency by 
transplacental passage of maternal anti-lgA antibodies has been 
suggested (13). Our observations indicate that the children also tend to 
develop anti-lgA antibodies before puberty. The girl with 
hypomagnesemia developed anti-lgA antibodies only after puberty at the 
age of eighteen. Concomitant lgG4-lgE deficiency was found in all four 
children. This could suggest the possibility of a predominance for 
development of anti-lgA antibodies in lgG4-lgE-lgA deficient individuals. A 
higher frequency of anti-lgA antibodies in Ід
 г
-ІдА deficient patients 
compared to isolated IgA deficient patients has been reported (20), but 
no information was given about the time of first occurrence of anti-lgA 
antibodies. Perhaps periodic screening for anti-lgA antibodies before 
puberty can be reserved for IgA deficient children of IgA deficient 
mothers with detectable anti-lgA antibodies and for IgA deficient children 
with concomitant IgG subclass and/or IgE deficiency. 
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Chapter 3 
IN VITRO IMMUNOGLOBULIN PRODUCTION BY LYMPHOCYTES 
IN A POKEWEED MITOGEN DRIVEN CULTURE SYSTEM: 
Methods and Calculations 

3.1 INTRODUCTION 
As outlined in Chapter 1, investigations on the cellular basis of selective 
IgA deficiency have been described in numerous reports over the past 
fifteen years (1-12). In most reports the capacity of peripheral blood 
mononuclear cells (PBMC) of IgA deficient individuals for pokeweed 
mitogen (PWM)-driven in vitro IgA production was studied. In some 
studies PBMC have been divided into non-T and Τ cells, usually by 
resetting techniques (5,6,8-12). Cocultures of patient non-T or Τ cell 
fractions with counterpart cell fractions of healthy controls enabled the 
discrimination of the role of В and/or Τ cell abnormalities in the 
pathogenesis of selective IgA deficiency. Low-dose irradiation of Τ cells 
has been demonstrated to abolish Τ suppressor function without 
affecting Τ helper activity (13). Another method for reliable distinction of 
Τ suppressor and Τ helper function in the Τ cell fraction is the use of 
cell fractions depleted in CD4+ or CD8+ cells by complement-mediated 
lysis using anti-T cell antibodies (11,12). 
In order to investigate the cellular basis of selective IgA deficiency 
in our patients, an in vitro cell culture system comparable to those used 
in earlier reports (9,11) was made operational in our laboratory. Patient 
В and Τ cell functions were studied by separating PBMC in non-T and Τ 
cell fractions, and culturing them with counterpart fractions of healthy 
controls. Τ suppressor and Τ helper activity were functionally 
distinguished by evaluating the effects of irradiation of the Τ cell 
fractions. The amounts of IgA and IgM secreted into the culture 
supernatants were measured. The cultured cells were examined for 
cytoplasmic IgA content in order to investigate the possibility of a 
secretory blockade for IgA as described by Waldmann et al. (3). 
3.2 THE CELL CULTURE SYSTEM 
3.2.1 Cell preparation 
PBMC were isolated from defibrinated venous blood of IgA deficient 
children (40-60 ml) and healthy controls (100-150 ml) by density gradient 
centrifugation on a layer of Ficoll-lsopaque (density 1.077). The 
defibrinated blood sample was diluted 1:1 with TRIS-buffered Eagle's 
Minimal Essential Medium (MEM, GIBCO Europe,Paisley,Scotland) 
containing 100,000 U Penicillin and 100 mg Streptomycin per liter (MEM-
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TRIS). Two volumes of diluted blood were pipetted on one volume of 
Flcoll-lsopaque. Centrifugation was carried out at "lOOOxg for 20 minutes 
at 20oC. The obtained PBMC from the interphase were washed two times 
with 5% fetal calf serum (FCS, Seralab,Crawley Down,England) in MEM-
TRIS. Erythrocytes were lysed for 10 minutes at 37°C with TRIS-buffered 
ammoniumchloride solution (0.14 mol/l, pH 7.2). 
Separation into Τ and non-T cell fractions was performed by a 
resetting technique with 2-aminoethyl isothiouroniumbromide hydro-
bromide-treated fresh sheep red blood cells (AET-SRBC). The AET-
SRBC suspension was prepared by first washing the sheep erythrocytes 
5 times with sterile saline, then mixing 1 volume of SRBC suspension 
with 4 volumes of AET solution (4 grams of AET per 100 ml, pH 9.0) and 
then incubating the mixture for 15 minutes at 370C. After four more 
washings with sterile saline a 1% AET-SRBC suspension in 20% 
FCS/MEM-TRIS was prepared. Equal volumes of a cell suspension con­
taining 4x10" PBMC per ml 5% FCS/MEM-TRIS and the cell suspension 
of 1% AET-SRBC in 20% FCS/MEM-TRIS were mixed and incubated for 
15 minutes at 370C, centrifuged and left overnight at 4°C. The next day 
the cell pellet was gently resuspended and centrifuged during 20 
minutes at 1000xg on a layer of Ficoll-lsopaque (density 1.085). 
Interphase cells (non-T cells) and cell pellet (T cells) were both washed 
two times with 5% FCS/MEM-TRIS, and SRBC were lysed with 
ammoniumchloride solution. 
The Τ and non-T cell fractions thus obtained were resuspended in a 
cell culture medium containing 25% FCS in RPMI 1640 (GIBCO) with 
addition of 2.0 mmol/l glutamine, and penicillin-streptomycin as des­
cribed above. 
3.2.2 Cell cultures 
The cultures always consisted of 3x10s cells in 1 ml of culture medium, 
and were incubated in round-bottomed tubes in triplicate for 9 days at 
370C in a 5% C02, high-humidity incubator. 
Unseparated PBMC of IgA deficient children and of controls were 
cultured in order to relate the number of cytoplasmic IgA-containing cells 
to the amount of IgA secreted in the culture supernatant. 
Non-T and Τ cell fractions of IgA deficient children and of controls 
were either autologously recombined, or cocultured with their respective 
counterpart cell fractions (Table 3.1). Cocultures consisted of 1.5x10s 
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non-T cells and 1.5x10" Τ cells, without correction for the number of 
monocytes. Each coculture, except in most experiments the 
recombination of patient non-T cells and control Τ cells, was also 
performed with irradiated Τ cells (3000 rads from a Cesium-sourced 
Gammacell 1000B blood cell irradiator; Isomedix Ine, Parsippany.NJ) to 
eliminate Τ suppressor function. Cells were cultured with and without 
stimulation by pokeweed mitogen (PWM, GIBCO Laboratories, Grand 
Island,NY) in a final dilution of 12.5 micrograms/ml medium. 
Supernatants were collected and stored at -20oC until determination of 
immunoglobulin (Ig) content. In most in vitro lg-production experiments 
two children with selective IgA deficiency were examined at the same 
time, employing the same healthy control for comparison and coculture 
techniques. 
Table 3.1: Cocultures performed within one patient-control combination. 
Control non-T cells 
Patient non-T cells 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Control 
Control 
Patient 
Patient 
Patient 
Patient 
Control 
Control 
Τ 
Τ* 
τ 
τ* 
τ 
τ* 
τ 
τ* 
cells 
cells 
cells 
cells 
cells 
cells 
cells 
cells 
T* = irradiated Τ cells 
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3.2.3 Immunoglobulin assays In the culture supernatant 
Supernatant IgA and IgM contents were measured in duplicate after nine 
days of culture using a class-specific enzyme-linked double-antibody 
immunosorbent assay (ELISA). Briefly, polystyrene 96-well, flat-bottomed 
microtiter plates (NUNC.Roskilde.Denmark) were coated overnight at 4°C 
with rabbit anti-human IgA or IgM gammaglobulin fraction 
(DAKO.GIostrup,Denmark) in 0.05 M sodiumbicarbonate (pH 9.6). After 
washing with phosphate-buffered saline (PBS), containing 0.05% Tween 
20, 100 microliter aliquots of tissue culture supernatant samples or 
reference serum diluted in tissue culture medium were added to the 
wells, and the plates were incubated for 90 minutes at 37QC. Next, the 
plates were washed again with PBS-Tween 20 and incubated for 90 
minutes at 37°C with horse-radish peroxidase (HRP)-labeled rabbit anti-
human IgA or IgM (DAKO). The plates were then washed again, and 
H202 with o-phenylenediamine-di-HCI as chromogene was added in 
citrate-phosphate buffer (pH 5.0). Color development was monitored 
spectrophotometrically at 492 nm by using an automated reader (Titertek 
Multiskan, Flow Labs, Maclean.VA). Values were expressed in terms of 
nanograms of Ig per milliliter of culture supernatant. Lowest limit of 
detection was 10 ng/ml for IgA and 20 ng/ml for IgM. The variation of 
the duplicate ELISA Ig measurements ranged 3-6% for both IgA and IgM. 
The variation in Ig production within the triplicate set of cultures ranged 
15-30% for both IgA and IgM. 
3.2.4 Detection of cytoplasmic IgA 
After removal of the supernatant, the cells of the triplicate set of culture 
tubes containing unseparated PBMC were combined. They were washed 
three times with a solution containing 60 ml PBS, 20 ml 20% bovine 
serum albumin (BSA, Organon Teknika.Oss.The Netherlands) and 2 ml 
5% EDTA-PBS (pH 7.8). The cells were fixed with 0.5% formaldehyde 
after the first washing procedure. Cytospin slides were made in the 
usual way, and cytoplasmic IgA was stained with fluorescein-labeled 
goat F(ab,)2 antihuman IgA (Kallestad,Austin,TX). IgA-containing cells 
were visualized using a Zeiss fluorescense microscope and expressed as 
a percentage of the total cell amount (at least 1000 cells were counted). 
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3.2.5 Determination of cell surface markers 
Lymphocytes isolated from defibrinated peripheral blood by the Ficoll-
Isopaque density gradient method were suspended in PBS with 1% BSA 
(PBS-BSA). 
Determination of surface Ig* cells: 
After washing in PBS-BSA at 4°C the cells were pre-incubated for 30 
minutes at 370C to remove adsorbed serum immunoglobulins. After two 
more washings in PBS-BSA at 40C
>
 50 microliter cell suspension (or 
2x10e cells) were mixed with 100 microliter diluted tetramethyl-rhodamine 
isothiocyanate (TRITC)-labeled polyclonal goat Р(аЬ')
г
 antihuman total 
immunoglobulins antiserum (Kallestad). Incubation was performed at 4°C 
during 20 minutes. After incubation the cells were washed 3 times with 
PBS-BSA + 0.02% sodium-azide at 40C for 30 minutes and placed on a 
slide with one drop of buffered glycerol. The slides were examined 
under a Zeiss Standard microscope equipped with a Ploem-type vertical 
illuminator, a high performance mercury lamp HBO 50 (Osram), and a 
suitable filter combination. 
Determination of CD4+, CD5* and CD8+ Τ cells: 
After three washings in PBS-BSA at 40C, 50 microliter cell suspension (or 
2x10е cells) were mixed with 100 microliter diluted monoclonal antiserum 
(Leu-1 (Becton Dickinson.Sunnyvale.CA) for CD5+-cell determination, 
OKT4 and OKT8 (Coulter Immunology,Hialeah,FL) for CD4+ and CD8* 
cells, respectively). After three washings with PBS-BSA at 4°C a second 
incubation was performed at 40C for 30 minutes with 100 microliter 
diluted fluorescein isothiocyanate (FITC)-labeled goat anti-mouse 
immunoglobulin antiserum. The cells were then washed three times with 
PBS-BSA + 0.02% sodium-azide at 40C for 30 minutes and thereafter 
placed on a slide with one drop of buffered glycerol and examined by 
immunofluorescence microscopy as described above. 
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3.3 CALCULATIONS 
After averaging the duplicate Ig measurements in the culture supernatant 
the results of certain cocultures within one patient-control combination 
were compared. Undetectable values were replaced by 5 ng/ml. The 
comparisons of cocultures used within one patient-control combination 
and the conditions set to define the pathogenic mechanisms of selective 
IgA deficiency are shown in Table 3.2. 
Table 3.2: Comparisons of certain cocultures within one patient-control combination 
used to distinguish different pathogenic mechanisms of selective IgA 
deficiency. 
COMPARISONS 
CONDITIONS SET FOR 
PATHOGENIC MECHANISMS 
Ts Th B+Ts B+Th 
PnonT + CT 
CnonT + PT 
CnonT + PT* 
CnonT + PT* 
PnonT + PT* 
CnonT + CT 
CnonT + CT 
CnonT + CT 
CnonT + PT 
PnonT + PT 
+ - -
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- (only for IgM) 
В 
Ts = 
Th = 
С 
Ρ 
nonT = 
Τ 
Τ* = 
+ 
— = 
defective Β cell function 
excessive Τ suppressor function 
diminished Τ helper function 
control 
patient 
non-T cells 
Τ cells 
3000 rad Irradiated Τ cells 
p-value <, 0.0125 for IgA (total ρ i 0.05) 
p-value й 0.0100 for IgM (total ρ S 0.05) 
not significant 
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Because of considerable differences in the variation of the values one­
sided t-tests modified according to Satterthwaite were used for the 
comparisons of cocultures within one patient-control combination 
(TTEST-SAS procedure). As shown in Table 3.2, full distinction of the 
possible pathogenic mechanisms necessitated multiple comparisons: four 
in case of in vitro IgA production and five in case of in vitro IgM 
production. The Bonferroni adjustment was applied to determine 
significance levels for analysis involving multiple comparisons. This 
implied a significance level of ρ = 0.0125 for in vitro IgA production 
(four comparisons) and ρ = 0.0100 for IgM (five comparisons). 
According to the Bonferroni adjustment (the sum of multiple tests), this 
results in a total significance level of ρ = 0.05 for the reliability of a 
pathogenic mechanism concluded from the results of the cocultures 
within one patient-control combination. 
3.4 INTERPRETATION OF THE CELL CULTURE RESULTS 
In previous reports defective IgA В cell function, excessive Τ suppressor 
function, diminished Τ helper function, and combinations of В and Τ cell 
abnormalities have been described as pathogenic mechanisms 
underlying selective IgA deficiency (3-12). 
Using the cell culture system described above it was possible to 
evaluate В and Τ cell functions for in vitro IgA production in our 
patients. The results of the coculture experiments within one patient-
control combination (Table 3.1) can be compared. The expected 
amounts of in vitro Ig production in the cocultures in case of defective В 
cell function, excessive Τ suppressor function, diminished Τ helper 
function and combinations of В and Τ cell abnormalities are shown in 
Figures 3.1-3.5. 
In vitro IgM production was measured simultaneously with in vitro 
IgA production in all cell cultures. Defective in vitro Ig production can be 
found in individuals who are so-called non-responders to stimulation with 
PWM. Another possibility can be the generation of Τ suppression in 
cocultures of allogeneic cells, which has been reported to occur in 1% 
of randomly chosen combinations (13). By measuring simultaneous IgM 
production in the cell culture supernatants these two possible causes of 
defective in vitro IgA production can be excluded, as they are not 
isotype-specific. 
53 
3.4.1 Diminished В cell function (Figure 3.1, Table 3.2) 
Diminished В cell function (B) was concluded if Ig production by 
cocultures of patient non-T cells + control Τ cells was significantly lower 
than Ig production by recombined control non-T + Τ cells (comparison 
1: PnonT+CT * CnonT+CT: +). 
CnonT+CT CnonT+PT PnonT+PT PnonT+CT 
Figure 3.1: Diminished В cell function. In vitro Ig production by lymphocytes from a 
healthy control person and a patient with selective IgA deficiency. 
Cocultures were performed after recombination of equal numbers of 
non-T and Τ cells (1.5x10s). С = control; Ρ = patient; open bars 
represent cocultures with nonirradiated Τ cells; striped bars cocultures 
with irradiated Τ cells. 
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3.4.2 Excessive Τ suppressor function (Figure 3.2, Table 3.2) 
Excessive Τ suppressor function (Ts) was only concluded if the following 
conditions were all three fulfilled: 
1) Ig production by cocultures of control non-T + patient Τ cells must 
be significantly lower than Ig production by recombined control non-
T + Τ cells (comparison 2: CnonT+PT <, CnonT+CT: +); 
2) Ig production by cocultures of control non-T + irradiated patient Τ 
cells must not be significantly different from Ig production by 
control non-T + Τ cells (comparison 3: CnonT+PT* < CnonT+CT:-); 
3) Ig production by cell cultures containing irradiated patient Τ cells 
must be significantly higher than Ig production by cell cultures 
containing non-irradiated patient Τ cells (comparison 4: CnonT+PT* 
> CnonT+PT: +; and for IgM production also comparison 5: 
PnonT+PT* > PnonT+PT: +). 
ig 
π 
1 
Р^ 
j 
Р^ 
Уу 
CnonT+CT CnonT+PT PnonT+PT PnonT+CT 
figure 3.2: Excessive Τ suppressor function (legend as in Figure 3.1). 
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3.4.3 Diminished Τ helper function (Figure 3.3, Table 3.2) 
Diminished Τ helper function was only concluded if the following 
conditions were all three fulfilled: 
1) Ig production by cocultures of control non-T + patient Τ cells must 
be significantly lower than Ig production by recombined control non-
T + Τ cells (comparison 2: CnonT+PT <, CnonT+CT: +); 
2) Ig production by cocultures of control non-T + irradiated patient Τ 
cells must be significantly lower than Ig production by control non-T 
+ Τ cells (comparison 3: CnonT+PT* s CnonT+CT: +); 
3) Ig production by cell cultures containing irradiated patient Τ cells 
must not be significantly higher than Ig production by cell cultures 
containing non-irradiated patient Τ cells (comparisons 4: 
CnonT+PT* * CnonT+PT: -, and for IgM production also 
comparison 5: PnonT+PT* > PnonT+PT: - ) . 
CnonT+CT CnonT+PT PnonT+PT PnonT+CT 
Figure 3.3: Diminished Τ helper function (legend as in Figure 3.1). 
56 
3.4.4 Diminished В cell function combined with excessive Τ 
suppressor function (Figure 3.4, Table 3.2) 
All conditions set above for both diminished В cell function and 
excessive Τ suppressor function must be fulfilled before this could be 
concluded (comparisons 1: + . 2 : +, 3: -, 4: +, and for IgM also 5: +). 
CnonT+CT CnonT+PT PnonT+PT PnonT+CT 
Figure 3.4: Diminished В cell function combined with excessive Τ suppressor 
function (legend as in Figure 3.1). 
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3.4.5 Diminished В cell function combined with diminished Τ 
helper function (Figure 3.5, Table 3.2) 
All condit ions set above for both diminished В cell function and 
diminished Τ helper function must be fulfi l led before this could be 
concluded (comparisons 1: + . 2 : + , 3: + , 4: -, and for IgM also 5: - ) . 
ig 
РЯ 
^d г~гя YZL YZL 
CnonT+CT СпопТ+РТ ΡηοηΤ+ΡΤ ΡηοηΤ+CT 
Figure 3.5: Diminished В cell function combined with diminished Τ helper function 
(legend as in Figure 3.1). 
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Chapter 4 
IN VITRO IMMUNOGLOBULIN PRODUCTION IN CHILDREN WITH 
SELECTIVE IgA DEFICIENCY IN RELATION TO 
CLINICAL MANIFESTATIONS 
P.C.J, de Laat, C.M.R. Weemaes, J.A.J.M. Bakkeren, 
F.C.A. van den Brandt, T.G.P.M. van Lith, R. de Graaf*, 
P.J.J, van Munster, G.В.A. Stoelinga. 
Department of Pediatrics and *Medical Statistics 
University Hospital Nijmegen 
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4.1 ABSTRACT 
Twentytwo children with selective IgA deficiency (14 "sporadic" and 8 
"familial") were investigated for pokeweed mitogen-driven in vitro 
immunoglobulin production. A defect in IgA production by peripheral 
blood mononuclear cells was established in all patients but one. In four 
children also in vitro IgM production was below the range of healthy 
controls. Cocultures performed with patient and/or control non-T and Τ 
cells revealed а В cell defect for in vitro IgA production in all but one of 
the patients. Nine patients had a pure В cell defect, but in 12 patients 
additional Τ cell regulatory disturbances could be established. IgA-
specific excessive Τ suppressor function was found in 3 patients. IgA-
specific diminished Τ helper function was found in 4 patients, and 
diminished Τ helper function for both in vitro IgA and IgM production 
could be demonstrated in 5 patients. Clinical manifestations in children 
with pure В cell defects or with В cell defects and additional IgA-specific 
Τ cell abnormalities were comparable: mainly mild respiratory tract 
infections and atopic complaints. It was noted that most of the patients 
with more severe infections or with complaints other than recurrent 
infections or atopy also had disturbances in in vitro IgM production. 
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4.2 INTRODUCTION 
Selective IgA deficiency is generally considered to be the most common 
primary immunodeficiency. Clinical manifestations of selective IgA 
deficiency vary from none at all to associations with the occurrence of 
various diseases as auto-immune disorders, recurrent infections, gastro­
intestinal complaints and atopic disease (1,2). Simultaneous occurrence 
of IgG subclass deficiencies (especially Ід6
г
 and/or lgG4) in patients with 
selective IgA deficiency have been reported, and were related to a high 
rate of infections (3,4). Investigations on the primary immune response 
of patients with selective IgA deficiency revealed general disturbances in 
humoral and cellular immunity to newly encountered antigens (5). Most 
cases of selective IgA deficiency are "sporadic", but familial occurrence 
with various patterns of inheritance is well-known (1,2,6). 
The results of studies on the cellular basis of selective IgA 
deficiency are diverse. Waldmann et al. reported a secretory blockade of 
IgA producing cells (7). Others attributed selective IgA deficiency to an 
inability of В cells to differentiate into IgA producing cells (8). In later 
studies a developmental defect in В cell differentiation was suggested as 
the major cause, although combinations of В and Τ cell functional 
abnormalities have been described in several patients (9-14). 
In the present study we investigated the cellular basis of selective 
IgA deficiency in 22 children. Our study included both "sporadic" and 
"familial" cases of selective IgA deficiency. Special regard was paid to 
the clinical manifestations and the possibility of differences in 
pathogenesis between both groups. 
4.3 METHODS 
4.3.1 Patients and controls 
Twentytwo children and adolescents with selective IgA deficiency were 
investigated (16 boys and 6 girls). The clinical history has been reported 
previously (15). Selective IgA deficiency was defined according to Hong 
and Ammann (16): serum IgA level: < 50 mg/liter, normal serum IgG and 
IgM levels, and no or at most mild abnormalities of Τ cell function. Two 
of the children formerly were IgA deficient, but had developed serum IgA 
levels just above 50 mg/l shortly before the in vitro experiments were 
performed. None of our patients had circulating anti-lgA antibodies. 
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Serum immunoglobulins were measured in all first degree relatives of our 
patients. Eight children had a sibling with IgA deficiency and were 
considered as "familial" cases. The 14 children without affected sibs 
were considered as "sporadic" cases. Age at the time of the cell culture 
experiments ranged from 3 to 21 years (median 11 years). 
The control group of eleven persons mainly consisted of healthy 
laboratory workers with normal serum immunoglobulin levels and intact 
in vitro immunoglobulin production in previous pilot experiments. 
4.3.2 Serum Immunoglobulin measurements 
Serum immunoglobulin levels were determined by laser-nephelometry 
using a DISC 120 Nephelometer (Hyland,Nivelles,Belgium), and all values 
were calibrated against WHO standard serum No.67/97. Serum IgA levels 
below the detection limit of the applied nephelometric technique (50 
mg/l), and, if present, the amount of class-specific anti-lgA antibodies 
were further quantitated with a radioimmunoassay (17). 
4.3.3 In vitro experiments 
Cell preparation and cell cultures were performed as described in 
Chapter 3. Briefly, peripheral blood mononuclear cells (PBMC) from 
patients and controls were isolated by density-gradient centrifugation 
and separated into Τ and non-T cell fractions. Τ and non-T cells from 
controls and patients were either autologously recombined or cocultured 
with respective counterpart cells in triplicate PWM-driven cell cultures. 
Each cell culture except PnonT+CT was also performed with irradiated Τ 
cells (3000 rads) to eliminate Τ suppressor function (18). IgA and IgM 
concentrations in the culture supernatants were measured by ELISA and 
expressed as nanograms of immunoglobulin per milliliter supernatant. 
After nine days of culture the number of cytoplasmic lgA+-cells was 
examined in cultures of unseparated PBMC from children with selective 
IgA deficiency or from healthy controls. 
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4.3.4 Calculations 
For comparison of in vitro IgA production by unseparated PBMC a 
Wilcoxon-test modified according to Gehan was used. Correlation 
between in vitro IgA production and the number of cytoplasmic IgA*-
cells was calculated according to Spearman. 
A one-sided t-test modified according to Satterthwaite was used for 
comparison of certain cocultures within one patient (TTEST-SAS 
procedure). The Bonferroni adjustment was applied to determine 
significance levels for analysis involving multiple comparisons. This 
implied a significance level of ρ = 0.0125 for IgA (four comparisons) and 
ρ = 0.01 for IgM (five comparisons). The conditions set to distinguish 
defective В cell function, excessive Τ suppressor function and diminished 
Τ helper function are shown in Table 4.1. 
Table 4.1: Comparisons of certain cocultures within one patient-control combination 
used to distinguish different pathogenic mechanisms of selective IgA 
deficiency (for explanation see also Chapter 3). 
1 = 
2 = 
3 = 
4 = 
5 = 
В 
Ts 
Th 
COMPARISONS 
= PnonT + CT 
= CnonT + PT 
= CnonT + PT* 
= CnonT + PT* 
= PnonT + PT* 
= defective 
excessive 
<. 
Í 
< 
> 
ϋ 
CnonT + CT 
CnonT + CT 
CnonT + CT 
CnonT + PT 
PnonT + PT 
В cell function 
Τ suppressor function 
diminished Τ helper function 
CONDITIONS SET FOR 
PATHOGENIC MECHANISMS 
В 
+ 
-
-
-
-
Ts 
_ 
+ 
-
+ 
+ 
Th 
_ 
+ 
+ 
-
-
С 
Ρ 
nonT 
Τ 
τ* 
B+Ts B+Th 
+ 
+ 
-
+ 
+ 
= 
= 
= 
= 
zs 
+ 
+ 
+ 
— 
- (only for IgM) 
control 
patient 
non-T cells 
Τ cells 
irradiated Τ cells 
+ = p-value $ 0.0125 for IgA (total ρ < 0.05) 
p-value < 0.0100 for IgM (total ρ < 0.05) 
- = not significant 
65 
4.4 RESULTS 
4.4.1 In vitro IgA production 
Unseparated PBMC or autologous recombinations of non-T and Τ 
cells 
Unseparated PBMC of healthy controls were able to synthesize and 
secrete IgA in vitro when stimulated by PWM (Table 4.2). After 
recombination of non-T and Τ cells of healthy controls, comparable 
amounts of IgA could be detected in the culture supernatant. 
Unseparated PBMC or recombined non-T and Τ cells of most chil­
dren with selective IgA deficiency were unable to produce significant 
amounts of IgA (Table 4.2). At the time the cultures were performed the 
children MJ and DF turned out to have serum IgA levels around, or just 
above, the limit of 50 mg/l used to define selective IgA deficiency (Table 
4.2). Afterwards, serum IgA levels in both patients remained above 50 
mg/l, although far below the lower range of age specific reference 
values. IgA production by their unseparated PBMC reached higher 
levels, and in one case (DF) was almost in the range shown by healthy 
controls. There was a significantly (p = 0.003) lower IgA production by 
unseparated PBMC in "sporadic" patients with selective IgA deficiency, 
compared to "familial" patients. If children with serum IgA levels above 
10 mg/l were left out of consideration, the difference still remained 
significant (p = 0.03). 
Cytoplasmic IgA 
The number of cytoplasmic lgA+-cells correlated well (r = 0.93; p<0.001) 
with the amount of IgA secreted into the culture supernatant. Compared 
to healthy controls significantly (p<0.001) lower numbers of cytoplasmic 
lgA+-cells were found after PWM-stimulated cell culture in children with 
selective IgA deficiency, leaving out DF (Table 4.2). Comparison of 
"sporadic" and "familial" cases of selective IgA deficiency revealed 
significantly (p = 0.01) lower numbers of cytoplasmic IgA containing cells 
in the "sporadic" cases. The difference remained significant (p = 0.02) if 
children with serum IgA levels above 10 mg/l were left out of 
consideration. 
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Table 4.2: Serum IgA levels and In vitro IgA production in selective IgA deficient 
children and healthy controls. 
In vitro IgA production" 
Patients 
Sporadic 
SvB 
BK 
BS 
TjJ 
MB 
PM 
MvdB 
RvdB 
IA 
PdG 
ED 
WL 
DQ 
DJ 
Familial 
RF 
DF 
MM 
TM 
MJ 
TJ 
MD 
PD 
Controls 
(n = 11) 
mean 
range 
serum IgA 
(mg/l) 
0.59 
0.35 
0.43 
0.65 
0.80 
0.23 
19.41 
2.37 
0.23 
0.53 
11.0 
0.22 
0.2Θ 
0.48 
0.28 
45.1 
0.58 
0.28 
75.0 
0.48 
1.50 
21.2 
2900 
(1000-5460) 
cytoplasmic IgA' 
(%) 
0.1 
0.2 
0.2 
<0.1 
<0.1 
<0.1 
0.2 
0.1 
<0.1 
<0.1 
0.6 
<0.1 
<0.1 
0.1 
0.5 
2.4 
0.4 
0.1 
0.7 
0.4 
<0.1 
0.8 
4.1 
(2-10) 
PBMC 
(ng/ml) 
14 
13 
34 
<10 
<10 
28 
90 
<10 
16 
<10 
35 
10 
<10 
16 
25 
645 
40 
59 
102 
95 
<10 
248 
1737 
(698-4884) 
recombined 
(ng/ml) 
16 
12 
41 
<10 
<10 
31 
89 
<10 
15 
10 
35 
11 
<10 
<10 
27 
478 
27 
21 
74 
37 
<10 
51 
1314 
(502-4403) 
* The number of cytoplasmic IgA-containing cells after nine days culturing of 
unseparated PBMC is presented as a percentage of the total cell amount on the 
cytospin slide. 
ь
 In vitro IgA production by PBMC or recombined non-T and Τ cells is shown as 
calculated mean of each triplicate set of cultures after averaging the duplicate 
measurements. 
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Cocultures of поп-T and Τ cells 
A pure В cell defect was found in 6 patients (Table 4.3). In 4 of our 
patients (SvB, BK, RF and DF) no defect for in vitro IgA production 
could be concluded from the statistical comparisons of certain 
cocultures (Table 4.3). However, in patients SvB, BK and RF, 
comparison 1 (PnonT+CT s CnonT+CT) was almost significant (0.0125 
< ρ < 0.025, Bonferroni adjustment for four comparisons: total ρ <, 0.10). 
It has to be noted that the variation in the triplicate IgA measurements 
of the control used in these patients was rather large (Table 4.3). The 
numbers of cytoplasmic IgA-positive cells after PWM-driven culture 
(Table 4.2) and also in vitro IgA production in cultures containing patient 
non-T cells were very low in these three patients (Table 4.3). In our 
opinion these 3 patients also had an IgA В cell defect. Up to the present 
their serum IgA levels remained below 50 mg/l. Only patient DF revealed 
a low-normal number of cytoplasmic IgA-positive cells after PWM-driven 
culture and demonstrated almost normal in vitro IgA production, in spite 
of his up till now markedly depressed serum IgA levels. 
Table 4.3: Patients without Τ cell defects for in vitro IgA production. 
PATIENTS IN VITRO IgA PRODUCTION (ng/ml) 
C n o n T + C T C n o n T + C T * CnonT+PT CnonT+PT* PnonT+PT PnonT + PT* PnonT + CT 
Sporadic 
BS 548 t 33 
TjJ 502 ± 108 
MB 995 ι 165 
PM 1270 ± 96 
121 ± 60 439 ± 70 194 ± 4 4 41 ± 3 43 ± 8 45 ± 12 
2 1 8 3 t 4 3 7 298 ± 39 1164 ι 106 < 1 0 25 ι 12 < 1 0 
1535 ± 181 585 ± 171 832 ± 145 < 1 0 < 1 0 61 t 19 
1718 ι 63 953 t 98 1274 ± 292 31 t 8 29 ± 12 159 ι 50 
MvdB 4403 ι 537 
SvB 821 ι 218 
BK 821 ± 2 1 8 
4703 ± 475 
380 ± 148 
380 ± 148 
965 ± 360 
528 ± 110 
317 ± 28 
2586 ± 140 
716 ± 99 
112 ± 31 
89 ± 18 
16 ± 10 
12 ± 4 
98 ± 27 
77 ± 25 
11 ι 4 
260 ι 28 
58 ± 12 
141 ± 22 
Familial 
MM 788 ± 34 1040 ± 41 655 ± 160 620 ± 24 27 ± 6 < 1 0 106 ± 31 
RF 
DF 
866 ± 257 
866 ± 257 
2031 ± 137 
2031 ± 137 
430 ± 39 
625 ± 179 
319 ± 195 
378 ± 39 
27 ± 12 
478 ± 64 
< 1 0 
206 ± 27 
41 ± 27 
508 ± 106 
С - control . Ρ •• 
Τ = T celle. Τ* 
patient. ηοηΤ •» non-T cells. 
= 3000 rad irradiated Τ cells. 
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In the remaining 12 patients also а В cell defect for PWM-driven in 
vitro IgA production could be established, but they had disturbances in 
Τ cell function as well (Tables 4.4 and 4.5). А В cell defect with co­
existence of IgA-specific excessive Τ suppressor function was concluded 
in two of the "sporadic" and in one of the "familial" patients (Table 4.4). 
Table 4.4: Patients with an Intrinsic В cell defect for in vitro IgA production and 
additional IgA-specific excessive Τ suppressor function (B+Ts). 
PATIENTS IN VITRO IgA PRODUCTION (ng/ml) 
CnonT + CT C n o n T + C T * CnonT+PT CnonT+PT* PnonT+PT PnonT+PT* PnonT + CT 
Sporadic 
RvdB 995 ± 165 1535 t 181 475 1 67 783 ± 88 < 1 0 29 ± 4 60 t 68 
IA 4403 t 537 4703 ± 475 1866 ± 3 4 8 3774 ± 96 15 ± 1 1 24 ± 1 5 102 ± 37 
Familial 
PD 1627 ± 184 1692 ± 296 405 ± 61 1133 ± 1 8 1 51 ± 29 111 ± 24 227 ± 40 
С « control . Ρ =* patient. nonT = non-T cells. 
Τ - Τ cells. Τ* - 3000 rad irradiated Τ cells. 
А В cell defect with co-existence of diminished Τ helper function was 
concluded in five of the "sporadic" patients and in four of the "familial" 
patients (Table 4.5). The diminished Τ helper function was found to be 
IgA-specific in the two brothers MJ and TJ, and in one patient of family 
D. In the "sporadic" patient PdG comparison 2 was statistically 
significant (CnonT+PT <, CnonT+CT; p=0.009) l but this finding has to 
be regarded in the context of the unusually small variation of the 
triplicate IgA measurements found In the cocultures of this patient (Table 
4.5). Perhaps he should be regarded as having solely a pure В cell 
defect for in vitro IgA production. 
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Table 4.5: Patients with an intrinsic В cell defect for In vitro IgA production and 
additional diminished Τ helper function (B+Th). 
PATIENTS IN VITRO IflA PRODUCTION (ng/ml) 
CnonT+CT CnonT+CT* CnonT+PT CnonT+PT* ΡηβηΤ+РТ PnonT+PT* PnonT+CT 
Sporadic 
PdQ 1563 t 24 
689 ι 79 
1270 t 96 
952 ι 125 
548 ± 33 
ED' 
WL* 
DG' 
DJ' 
Familial 
MJ 2061 i 217 
TJ 2061 ±217 
MO 1627 ± 164 
TM* 788 ± 34 
4649 l 673 
134 t 22 
1718 t 63 
554 t 85 
121 ± 60 
1246 t 138 
1246 t 138 
1692 t 296 
1040 t 41 
1239 i 88 
65 ι 12 
345 ι 80 
220 t 28 
285 ι 68 
1100 t 245 
939 ι 241 
511 ± 108 
506 ι 81 
1223 t 34 
71 ι 12 
155 ± 47 
162 ± 19 
161 ± 39 
1347 ± 120 
731 ι 142 
399 ± 107 
519 ± 77 
10 
35 t 
11 ι 
<10 
<10 
74 ± 19 
37 ± 14 
<10 
21 ± 6 
<10 
<10 
47 t 13 
<10 
<10 
135 ι 23 
43 t 5 
<10 
<10 
54 t 7 
110 ι 35 
37 ι 16 
34 i 17 
28 t 2 
90 ± 9 
66 ± 17 
153 ι 18 
60 t 9 
С = control. Ρ = patient. nonT = non-T cells. 
Τ = Τ cells. Τ* " 3000 rad irradiated Τ cells. 
diminished Τ helper function also for In vitro IgM production. 
4.4.2 In vitro IgM production 
In vitro IgM production in healthy controls showed a considerable inter-
individual variation: ranging from 1319 to 17467 (mean 8655) ng IgM/ml 
in cultures of unseparated PBMC, and from 683 to 17243 (mean 6869) 
ng IgM/ml in cultures of recombined control non-T and Τ cells. In vitro 
IgM production in our patients was within the range of the controls (data 
not shown), except in patients TjJ, RvdB, DG and MB. Only the latter 
patient also had low serum IgM levels (around 40 Ill/ml), serum IgM 
levels in the other three were normal compared to age and sex specific 
reference values. 
Excessive Τ suppressor function for in vitro IgM production was not 
found in our patients. In 5 children (patients ED, WL, DG, DJ and TM) 
diminished Τ helper function for in vitro IgM production (and in vitro IgA 
production) could be established. 
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4.4.3 Clinical manifestations 
The clinical manifestations in our patients recorded during the follow-up 
period and the pathogenic mechanism for defective in vitro IgA 
production concluded from the cell culture experiments are briefly 
summarized in Table 4.6. 
The children with pure IgA В cell defects mainly suffered from 
recurrent respiratory tract infections (bronchitis, otitis). They never got 
serious illnesses. Three patients demonstrated а В cell defect in 
combination with IgA-specific excessive Τ suppressor function (Table 
4.4). The two "sporadic" patients had only mild infections; one of them 
also had an allergic rhinitis despite IgE deficiency and developed 
diabetes mellitus later on. The girl of the "familial" group suffered from 
coeliac disease. The patients with а В cell defect in combination with 
IgA-specific diminished Τ helper function (Table 4.5) had only mild 
clinical symptoms. One boy suffered from bloody stools; a diagnosis 
was never made and the problem disappeared spontaneously. 
An IgA В cell defect combined with a diminished Τ helper function 
for both in vitro IgA and IgM production was demonstrated in five 
children (Table 4.5). Four of them were "sporadic" cases. WL developed 
Crohn's disease after puberty. ED had recurrent urinary tract infections, 
but he had a vesico-ureteric reflux. Two patients have developed more 
severe infections, not occurring in the other IgA deficient patients: DJ 
was treated for osteomyelitis and DG had several episodes of 
lymphadenitis requiring surgical treatment. 
In four children in vitro IgM production by PBMC was below the 
range of controls. Patient DG with recurrent lymphadenitis has already 
been mentioned above. Patient TjJ suffered from bloody stools and 
developed Crohn's disease at the age of seventeen. Patient MB had 
severe recurrent respiratory tract infections requiring long-term 
prophylactic antibiotical therapy. Patient RvdB had recurrent otitis media 
during the whole follow-up period of 10 years. 
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Table 4 6 Clinical manifestations and pathogenic mechanisms concluded from the in 
vitro experiments in the patients 
PATIENTS 
Sporadic 
SvB 
BK 
BS 
TjJ ' 
MB* 
PM 
MvdB 
RvdB' 
IA 
PdG 
ED 
WL 
DG* 
DJ 
Familial 
RF 
DF 
MM 
TM 
MJ 
TJ 
MD 
PD 
Pathogenic 
mechanisms 
-
-
В 
В 
в 
в 
в 
B+Ts 
B + Ts 
B+Th 
B+Th" 
B+Th" 
B+Th b 
B+Th b 
-
-
В 
B+Th" 
B+Th 
B+Th 
B+Th 
B+Ts 
age 
16 
12 
12 
13 
9 
18 
11 
6 
10 
13 
3 
21 
10 
10 
7 
5 
g 
5 
15 
13 
11 
9 
sex 
M 
F 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
F 
M 
M 
M 
M 
M 
M 
M 
F 
F 
CLINICAL MANIFESTATIONS 
RRTI 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
AD 
+ 
+ 
+ 
+ 
+ 
+ 
Other 
Bloody stools 
Ring-chromosome 22 
Diabetes mellitus 
Urinary tract infections 
Crohn's disease 
Lymphadenitis 
Osteomyelitis 
Arthralgia 
Coellac disease m early 
childhood 
Bloody stools 
Coeliac disease 
RRTI = recurrent respiratory tract infections 
AD = atopic disease 
В = diminished В cell function 
Ts = excessive Τ suppressor function 
Th = diminished Τ helper function 
* = in vitro IgM production below the range of healthy controls 
" = diminished Τ helper function also for in vitro IgM production 
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4.5 DISCUSSION 
In all children investigated in this study except one а В cell defect for 
PWM-driven in vitro IgA production was found. Pure В cell defects were 
only found in a minority of our patients. The regulation of В cell 
differentiation to IgA-secreting plasma cells is not fully understood (19). 
It is known that this process is profoundly influenced by Τ cells and Τ 
cell-derived cytokines (19,20). In the present study coculture 
experiments revealed regulatory Τ cell disturbances in addition to 
defective IgA В cell function in 12 out of 22 children with selective IgA 
deficiency. Pure Τ cell defects did not occur. There were no obvious 
differences between "sporadic" and "familial" cases. 
А В cell defect in combination with IgA-specific excessive Τ 
suppressor function was found in 3 children. Excessive Τ suppressor 
function has been reported previously, but only in a few patients it was 
concluded to be exclusively responsible for IgA deficiency (10). In most 
other reported cases excessive Τ suppressor function either was not 
IgA-specific and/or combined with В cell defects (9-12). Studies by 
Lynch and co-workers using murine plasmacytomas as monoclonal В cell 
models revealed the existence of IgA-specific Τ suppressor cells that 
acted directly on В cells (21). The involvement of regulatory mechanisms 
exercised by Τ suppressor cells on expression and function of 
immunoglobulin mRNA in IgA В cells has been demonstrated (22). 
Recently we described two families in which IgA deficient mothers with 
circulating anti-lgA antibodies each had two children with selective IgA 
deficiency. In vitro experiments similar to those in the present study 
revealed an IgA В cell defect and IgA-specific excessive Τ suppressor 
function in all four children (14). Considering these findings it is possible 
that the IgA-specific excessive Τ suppressor function found in three of 
the patients in the present study indeed contributed to the pathogenesis 
of their selective IgA deficiency. 
An IgA В cell defect in combination with an IgA-specific diminished 
Τ helper function was found in 4 patients. To our knowledge the 
combination of defective В cell function with IgA-specific diminished Τ 
helper function has not been reported before in selective IgA deficiency. 
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The reliability of Τ cell dysfunction as a pathogenic mechanism 
would be strengthened by demonstrating identical findings within one 
family. In family J the same pathogenic mechanism was established in 
both family members. In family M only one of the children (TM) had co­
existence of diminished Τ helper function. In family D conflicting data 
were found: MD showed co-existence of IgA-specific diminished Τ helper 
function, whereas her sister PD demonstrated co-existence of IgA-
specific excessive Τ suppressor function. So it remained questionable 
whether Τ cell abnormalities (found in connection with defective IgA В 
cell function) represented a primary cause or became manifest later on 
in life. 
The clinical picture of the patients with pure В cell defects and 
those with В cell defects and IgA-specific Τ cell regulatory disturbances 
was comparable: atopic disorders and mild respiratory tract infections. 
In none of our patients excessive Τ suppressor function for in vitro IgM 
production could be established, while in several patients diminished Τ 
helper function was found for both in vitro IgA and IgM production. It 
has to be noted that most children with complaints other than recurrent 
respiratory tract infections or atopy also had disturbances in in vitro IgM 
production. Diminished in vitro IgM production despite normal serum IgM 
levels has been reported previously in patients with selective IgA 
deficiency (13,14,23). Decreased primary immune responses have been 
demonstrated in IgA deficient patients: in spite of normal and even 
elevated serum IgM and IgG levels there was a significantly lower 
response of the IgM and IgG anti-haemocyanin antibodies (5). One of 
our patients (WL) was investigated with haemocyanin too and showed a 
decreased IgM response whereas his IgG response was normal. 
It has to be considered that a certain category of individuals with 
selective IgA deficiency in fact has a more severe immunodeficiency in 
which immune responses in other immunoglobulin classes than IgA are 
affected. In some patients with selective IgA deficiency development of 
common variable immunodeficiency (CVID) has been documented 
(15,24). The immunologic dysregulations implicated in the pathogenesis 
of CVID are heterogeneous and resemble those in selective IgA 
deficiency: intrinsic В cell defects and regulatory Τ cell disturbances 
(24). Recently it was demonstrated that individuals with IgA deficiency 
and CVID share polymorphisms of MHC class III genes, suggesting that 
these disorders indeed are related (25). Both are known for their 
association with the development of auto-immune diseases. One of the 
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МНС supratypes shared in common is strongly associated with antibody-
mediated autoimmune diseases, although the mechanism is still unknown 
(26). The heterogeneity of clinical manifestations in patients with 
selective IgA deficiency possibly is based on the fact that some of them 
are shifting towards the development of CVID. This hypothesis is 
supported by the disturbances in in vitro IgM production found in some 
of our patients. 
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Chapter 5 
FAMILIAL SELECTIVE IgA DEFICIENCY WITH 
CIRCULATING ANTI-lgA ANTIBODIES 
A distinct group of patients? 
P.C.J, de Laat, C.M.R. Weemaes, J.A.J.M. Bakkeren, 
F.CA. van den Brandt, T.G.P.M. van Lith, R. de Graaf*, 
P.J.J, van Munster, G.В.A. Stoelinga. 
Department of Pediatrics and *Medical Statistics 
University Hospital Nijmegen 
The Netherlands 
Clinical Immunology and Immunopathology 1991;58:92-101 
5.1 ABSTRACT 
Two families were investigated in which the mothers had selective IgA 
deficiency and circulating class-specific anti-lgA antibodies. Both gave 
birth to two children who were found to be IgA deficient. Three of these 
children developed anti-lgA antibodies before puberty. In vitro 
immunoglobulin production studies performed in the children of both 
families revealed an IgA В cell defect combined with IgA-specific 
excessive Τ suppressor function in all four. The mechanisms by which 
transplacental passage of maternal anti-lgA antibodies could have 
interfered with the developing IgA system in the offspring are discussed. 
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5.2 INTRODUCTION 
Selective IgA deficiency is considered to be the most common primary 
immunodeficiency. Although most cases of IgA deficiency are "sporadic", 
the occurrence of "familial" selective IgA deficiency with various patterns 
of inheritance has been described (1-3). 
The incidence of anti-lgA antibodies in patients with selective IgA 
deficiency has been reported in percentages up to 40% (1). The reason 
why a substantial number of selective IgA deficient patients develop anti-
lgA antibodies and others do not is unknown. A relationship with 
previous administration of gamma-globulin or blood transfusion usually 
cannot be established when studying large groups of IgA deficient 
patients with anti-lgA antibodies, but is well known in individual cases. 
Presence of anti-lgA antibodies may result in hazardous reactions after 
transfusion of IgA-containing products (4-6). The role of anti-lgA 
antibodies in pathogenesis and/or maintenance of selective IgA 
deficiency is not clear. The possibility of induction of selective IgA 
deficiency by transplacental passage of maternal anti-lgA antibodies has 
been suggested (7-8). 
Investigations on the cellular basis of selective IgA deficiency 
reported previously showed varying results. The majority suggest a 
developmental defect in IgA В cell differentiation, but disturbances in 
regulatory Τ cell functions for in vitro IgA production have also been 
demonstrated (9-12). 
In this study we report our findings in two families in which IgA 
deficient mothers with class-specific anti-lgA antibodies gave birth to 
children who were also found to be IgA deficient. One family has been 
reported earlier (7), and additional follow-up is presented here. The 
cellular basis of selective IgA deficiency was investigated in the children 
of both families by means of in vitro immunoglobulin production 
experiments. 
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5.3 PATIENTS AND METHODS 
5.3.1 Patients 
In each family there were two children and a mother with selective IgA 
deficiency. Selective IgA deficiency was defined according to Hong and 
Ammann (13): serum IgA level: <50 mg/liter, normal serum IgG and IgM 
levels, and no or at most mild abnormalities of Τ cell function. Both 
fathers had normal serum IgA levels. There were no other children in the 
families. 
Family Τ has been described extensively in a previous report (7). 
The mother (TW) was known in our hospital with selective IgA deficiency 
and anti-lgA antibodies. She gave birth to two children. Anti-lgA 
antibodies obviously had been transported across the placenta as they 
could be demonstrated in the cord serum and in the serum of the 
children after the first week of life (7). The elder boy (NT) remained IgA 
deficient and developed anti-lgA antibodies himself at the age of 3.5 
years. His younger brother (YT) initially developed normal serum IgA 
levels in his first year of life (7), but was found to be IgA deficient at the 
age of five when he was reexamined. Anti-lgA antibodies could not be 
detected in his case as yet. Secretory IgA was measured in saliva and 
was not detectable (<2 mg/liter) in the mother and in NT. In the case of 
YT a level of 30 mg/liter of secretory IgA was found in saliva at the age 
of one. Secretory IgA was no longer detectable at the age of five. 
The proband in Family L. was a 7-year-old girl (WL) referred to our 
department because of recurrent respiratory tract infections. She was 
found to be IgA deficient and anti-lgA antibodies were present. Family 
studies revealed a younger sister (AL) with selective IgA deficiency who 
developed anti-lgA antibodies 5 years later at the age of nine. Their 
mother (ML) was IgA deficient too, and anti-lgA antibodies were found to 
be present. Secretory IgA was not detectable in saliva in all three. 
Immunoglobulin studies during pregnancy and in the first years of life of 
the children from this family are not available. 
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5.3.2 Control 
The control person used for the coculture experiments reported in this 
study was a healthy 30-year-old laboratory assistant with normal serum 
immunoglobulin levels and intact in vitro Ig production In previous pilot 
experiments. 
5.3.3 Serum Immunoglobulin measurements 
IgG, IgA, and IgM levels were determined by laser nephelometry using a 
DISC 120 Nephelometer (Hyland, Nivelles, Belgium). Serum IgA levels 
below the detection limit of the applied nephelometric technique (50 
mg/liter) were further quantitated with a solid-phase radioimmunoassay 
(14). Class-specific anti-lgA antibodies were determined by a titration 
radioimmunoassay as described previously (7,14). IgG subclass levels 
were determined by radial immunodiffusion and calibrated against 
reference serum. The reference serum contained 6.2 g/liter IgG,, 2.4 
g/liter IgGj, 0.64 g/llter IgGa and 0.46 g/liter lgG4. IgG subclass levels 
were expressed as a percentage of the reference serum. Levels below 
10% of the standard serum were considered as an indication for IgG 
subclass deficiency. Serum IgD levels were determined by ELISA and 
IgE levels by a radioimmunoassay. The lowest limit of detection was 1 
lU/ml for IgD and 2 lU/ml for IgE. Undetectable values were considered 
as an indication for IgD or IgE deficiency. 
5.3.4 Cell preparation 
Peripheral blood mononuclear cells (PBMC) were isolated from 
defibrinated venous blood of patients and the control person by Ficoll-
Isopaque density gradient centrifugation. After two wash steps 
erythrocytes were lysed with ammonium chloride solution. Separation 
into Τ and non-T cell fractions was performed by a rosetting technique 
with 2-aminoethylisothiouronium bromide hydrobromide-treated fresh 
sheep red blood cells (AET-SRBC). The Τ and non-T cell fractions thus 
obtained were resuspended in a cell culture medium containing 25% 
fetal calf serum (Seralab, Crawley Down, England) in RPMI 1640 (GIBCO 
Europe, Paisley, Scotland) with the addition of 2.0 mmol/liter glutamine, 
100,000 U/liter penicillin and 100 mg/liter streptomycin. 
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Investigations on cell surface markers were performed using 
fluorescence microscopy. Surface Ig* cells were stained with rhodamine-
labeled polyclonal goat Р(аЬ')
г
 anti-human total immunoglobulins 
antiserum (Kallestad, Austin, TX). CD5+ Τ cells were stained in an 
indirect method using Leu-1 monoclonal antiserum (Becton Dickinson, 
Sunnyvale, CA) and fluorescein-labeled goat anti-mouse immunoglobulin 
antiserum. CD4+ and CD8* Τ cells were stained in a similar way using 
OKT4 and OKT8 monoclonal antisera (Coulter Immunology, Hialeah, FL). 
5.3.5 Cell cultures 
Cultures always consisted of 3 χ 10' cells in 1 ml of culture medium and 
were incubated in round-bottomed tubes in triplicate for 9 days at 370C 
in a 5% СО
г
, high-humidity incubator. Unseparated PBMC were cultured 
in order to relate the number of cytoplasmic IgA-containing cells to the 
amount of IgA secreted in the culture supernatant. In two experiments Τ 
and non-T cell fractions of the children of each family and the control 
person were either autologously recombined or cocultured with their 
respective counterpart cell fractions. Cocultures consisted of 1.5 χ 105 
non-T cells and 1.5 χ 105 Τ cells, without correction for the number of 
monocytes. Each coculture was also performed with irradiated Τ cells 
(2000, 2500 or 3000 rad from a cesium-sourced Gammacell 1000B blood 
cell irradiator, Isomedix Ine, Parsippany, NJ) to eliminate Τ suppressor 
function (15). Cells were cultured with and without stimulation by 
pokeweed mitogen (PWM, GIBCO Laboratories, Grand Island, New York) 
in a final concentration of 12.5 ug/ml of culture medium. Supernatants 
were collected and stored at -20oC until determination of immunoglobulin 
content. 
5.3.6 Immunoglobulin assays In the culture supernatants 
Supernatant IgA and IgM contents were measured in duplicate after 9 
days of culture using a class-specific enzyme-linked double-antibody 
immunosorbent assay (ELISA). Briefly, coating was performed with rabbit 
anti-human IgA or IgM gammaglobulin fraction (DAKO, Glostrup, 
Denmark) and horseradish peroxidase-labeled rabbit anti-human IgA or 
IgM (DAKO) was used as second antibody. The chromogene was Н
г
О
г 
with ortho-phenylenediamine-di-HCI. Values were expressed in terms of 
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nanograms of Ig per milliliter. The lowest limit of detection was 10 ng/ml 
for IgA and 20 ng/ml for IgM. The variation of the duplicate ELISA 
immunoglobulin measurements ranged from 3 to 6% for both IgA and 
IgM. The variation in immunoglobulin production within the triplicate set 
of cultures ranged from 15 to 30% for both IgA and IgM. 
5.3.7 Detection of cytoplasmic IgA 
After removal of the supernatant, the cells of the triplicate set of culture 
tubes containing unseparated PBMC were combined. After washing and 
fixation with 0.5% formaldehyde, cytospin slides were made, and 
cytoplasmic IgA was stained with fluorescein-labeled goat F(ab')2 anti-
human IgA (Kallestad). IgA-containing cells were expressed as a 
percentage of the total cell amount (at least 1000 cells were counted). 
5.3.8 Calculations 
One-sided t tests modified according to Satterthwaite were used for 
comparison of cocultures within one patient (TTEST-SAS procedure). The 
Bonferroni adjustment was applied to determine significance levels for 
analysis involving multiple comparisons. This implied a significance level 
of ρ = 0.0125 for IgA (four comparisons) and ρ = 0.01 for IgM (five 
comparisons). 
5.4 RESULTS 
Immunological parameters and clinical manifestations of the IgA deficient 
members of both families are presented in Table 5.1. In all patients 
except YT, a concomitant lgG4-lgE deficiency could be demonstrated. 
Both mothers both showed elevated serum IgM levels. Surface lgA*-cells 
were absent in all patients. 
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Table 5.1: Immunological parameters and clinical manifestations of the IgA deficient 
members of both families. 
patients 
age in years 
serum Immunoglobulins 
IgG (lU/ml) 
IgA (mg/liter) 
IgM (lU/ml) 
IgD (lU/ml) 
IgE (lU/ml) 
IgG, (%)· 
lgG2 (%) 
lgG3 (%) 
IgG* (%) 
TW 
32 
113 
nd 
318 
< 1 
< 2 
150 
50 
92 
<10 
Family Τ 
NT 
10 
120 
nd 
81 
<1 
<2 
160 
20 
100 
<10 
YT 
7 
140 
4.3 
197 
120 
55 
160 
92 
98 
28 
ML 
35 
200 
nd 
448 
8 
< 2 
197 
152 
138 
<10 
Family L 
WL 
12 
99 
nd 
108 
<1 
<2 
105 
26 
78 
<10 
AL 
10 
110 
nd 
122 
<1 
< 2 
95 
50 
112 
<10 
antl-lgA antibodies" 1.1 nd 4.4 25 0.4 
Cell markers 
surface Ig* cells (%) 
surface IgA* cells (%) 
E-rosetting cells (%) 
10 
nd 
64 
13 
nd 
63 
18 
nd 
68 
14 
nd 
47 
20 
nd 
48 
8 
nd 
55 
Symptoms Gl OME none none RRTI none 
NOTE : nd = not detectable. Gl = gastro-intestinal: diarrhoea, giardiasis, follicular 
hyperplasia. OME = recurrent otitis media with effusion. RRTI = recurrent respiratory 
tract infections, bronchiectasies, impaired lung function. 
* IgG-subclass levels are expressed as a percentage of reference serum (HOO-020, The 
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service). 
" The titers of neutralizing antl-lgA antibodies are expressed in mg IgA/liter added (14). 
In vitro IgA production by unseparated PBMC and the number of 
cells staining for cytoplasmic IgA after PWM-stimulated cell culturing are 
presented in Table 5.2. Compared to healthy controls, in vitro IgA 
production and the number of cytoplasmic IgA containing cells were 
clearly lower in the patients with selective IgA deficiency. 
Table 5.2: PWM-stimulated culture of unseparated PBMC of both families with selective 
IgA deficiency. 
Family Τ 
NT 
YT 
Family L 
WL 
AL 
healthy controls 
(n-11) 
IgA-containing 
plasmacells' 
<0.1 
0.3 
<0.1 
<0.1 
2.0-10.0 
In vitro IgA 
production" 
< 1 0 
< 1 0 
< 1 0 
50 
698-4884 
* The number of cytoplasmic IgA-containing cells is expressed as a percentage of the 
total cell amount on the cytospln slide. 
" In vitro IgA production is expressed In terms of nanograms of IgA/ml of culture 
supernatant. 
In vitro Ig production by NT and YT in the cocultures is presented 
in Figure 5.1. WL and AL were investigated in a separate experiment 
using the same control person (Figure 5.2). Although the applied culture 
techniques were identical to those in the first experiment, the amounts of 
IgA and especially IgM measured in the culture supernatants of the 
second experiment turned out to be much lower. 
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Figures 5.1 and 5.2: In vitro IgA and IgM production by lymphocytes from a healthy 
control person a/id four children with 'familial' IgA deficiency. 
Cocultures were performed after recombination of equal numbers 
of поп-T and Τ cells (1.5x10'). С = control; Ρ = patient; open 
bars represent cocultures with nonirradiated Τ cells; striped bars 
cocultures with Irradiated Τ cells (2000, 2500 and 3000 rad, 
respectively). All values are expressed in terms of nanograms of 
immunoglobulin I ml and shown as the calculated mean of the 
triplicate set of each recombination. The line on top of the bars 
represents the standard deviation. 
IgA production by recombined patient non-T and Τ cells was absent 
or very low. Recombination of patient non-T cells with irradiated patient 
Τ cells revealed similar results. Coculture of patient non-T cells with 
control Τ cells resulted in detectable amounts of IgA production (Figures 
5.1 and 5.2). This was probably caused by residual non-T cells in the 
control Τ cell fraction (Table 5.3). This supposition is proven by the fact 
that if control Τ cells were irradiated prior to culture to eliminate 
immunoglobulin production by residual control non-T cells, IgA 
production again was absent or very low and comparable to that of 
recombined patient non-T and Τ cells (Figures 5.1 and 5.2). These 
findings evidence the existence of an intrinsic В cell defect in all 
children. 
Coculture of control non-T cells and patient Τ cells showed a 
significantly (p <, 0.0125) lowered in vitro IgA production compared to 
recombination of control non-T and Τ cells (Table 5.4). However, if 
patient Τ cells were irradiated prior to culture, in vitro IgA production in 
these cocultures was comparable to that of recombined control non-T 
and Τ cells (Figures 5.1 and 5.2). These findings indicate coexistence of 
radio-sensitive excessive Τ suppressor function besides the intrinsic В 
cell defect in all children. 
In vitro IgM production was measured simultaneously in all 
cocultures. In all children except WL, in vitro IgM production by 
recombined patient non-T and Τ cells and by cocultured patient non-T 
and control Τ cells was comparable to that of recombined control non-T 
and Τ cells, indicating normal in vitro IgM В cell function (Figures 5.1 
and 5.2). In the case of WL, IgM was undetectable in the culture 
supernatant after culturing recombined patient non-T and Τ cells. If her Τ 
cells were irradiated prior to culture, in vitro IgM production could be 
detected, but only in low amounts compared to the control person 
(Figure 5.2). 
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Table 5.3: Cell surface markers before and after separation of PBMC in non-T and Τ 
cell fractions. 
BEFORE SEPARATION 
surface Ig^-cells 
CD5*-cells 
CD4'-cells 
CD8+-cells 
(%) 
(%) 
<%> (%) 
Family Τ 
NT 
13 
54 
47 
7 
YT 
18 
54 
38 
10 
control 
13 
64 
39 
25 
Family L 
WL 
20 
49 
40 
9 
AL 
8 
45 
34 
9 
control 
11 
63 
-
-
AFTER SEPARATION 
non-T cells 
surface lg*-cells 
CD5+-cells 
Τ cells 
surface lg+-cells 
CD5*-cells 
CD4*-cells 
CD8+-cells 
(%) 
(%) 
(%) 
(%) 
(%) 
(%) 
32 
<1 
5 
80 
66 
10 
43 
2 
4 
77 
57 
14 
28 
1 
2 
84 
63 
25 
45 
<1 
4 
79 
69 
10 
22 
< 1 
1 
84 
65 
11 
36 
< 1 
2 
81 
52 
28 
The difference observed in all patients between in vitro IgM 
production of recombined control non-T and Τ cells and cocultured 
control non-T and patient Τ cells was not statistically significant (Table 
5.4). This indicates that there was no gross abnormality in the patients' 
Τ cell regulatory functions for In vitro IgM production. Regarding the 
cultures containing irradiated patient Τ cells, an elevation of in vitro IgM 
production was observed on several occasions (Figures 5.1 and 5.2), 
although not always statistically significant (Table 5.4). A comparable 
elevation of in vitro IgM production was noted if control non-T cells were 
recombined with irradiated control Τ cells (Figures 5.1 and 5.2). 
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Table 5.4: Analysis of coculture results using one-sided t-tests modified according to 
Satterthwaite (TTEST-SAS procedure). 
PATIENTS 
COMPARISONS NT YT WL AL 
IgA 
PnonT + CT 
CnonT + PT 
CnonT + PT* 
CnonT + PT* 
conclusion 
CnonT + CT 
CnonT + CT 
CnonT + CT 
CnonT + PT 
+ 
+ 
+ + -
B+Ts 
+ 
+ 
+ + + 
B+Ts 
+ 
+ 
+ + + 
B+Ts 
+ 
+ 
+ + + 
B+Ts 
IgM 
PnonT 
CnonT 
CnonT 
CnonT 
PnonT 
+ CT 
+ PT 
+ PT* 
+ PT* 
+ PT* 
CnonT + CT 
CnonT + CT 
CnonT + CT 
CnonT + PT 
PnonT + PT 
+ + - - + + + + + + -
conclusion 
NOTE: Ρ 
С 
PT* 
+ 
в 
TS = 
Patient 
Control 
irradiated patient Τ cells; 2000, 2500 or 3000 rad respectively 
p-value < 0.0125 for IgA (Total p-value й 0.05) 
p-value < 0.0100 for IgM (Total p-value й 0.05) 
not significant 
В cell defect: (PnonT+CT < CnonT+CT : +) 
excessive Τ suppressor function: (CnonT+PT* £ CnonT+CT : 
all other comparisons : +) 
5.5 DISCUSSION 
All four children in the two investigated families are IgA deficient. 
In Family Τ we were able to demonstrate transplacental passage of 
maternal anti-lgA antibodies (7). NT remained IgA deficient after birth. YT 
initially showed a rise in serum IgA levels and IgA was found present in 
saliva, but eventually he did not develop a mature IgA system. 
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We suggested the possibility of a disturbance in the IgA-specific Τ cell 
regulation, induced by maternal anti-lgA antibodies, and resulting in 
inhibition of IgA В cell differentiation and proliferation in the children (7). 
Two of the patients with selective IgA deficiency and disturbance in 
regulatory Τ cell function reported by Waldmann et al. (9) also had 
mothers with high titers of anti-lgA antibodies, and induction of allotype 
specific Τ suppressor cells in the progeny was suggested. 
Our investigations on the cellular basis of IgA deficiency in the 
children presented in this paper revealed an intrinsic В cell defect for in 
vitro IgA production in all four. The low numbers of cytoplasmic IgA 
containing cells after 9 days of culture evidenced that this В cell defect 
was not due to a secretory blockade. Furthermore, a coexisting 
excessive Τ suppressor function was found in all children. This probably 
appeared to be IgA-specific, as we were not able to demonstrate a 
clearly significant effect upon in vitro IgM production. 
It is known from several studies that administration of an anti­
immunoglobulin can lead to a state of idiotype-specific suppression 
which, once established, can be transferred by Τ cells (16-18). In a 
sequence of studies by Lynch and co-workers (reviewed in Ref.(19)) 
using murine plasmacytomas as monoclonal В cell models, 
immunoglobulin-specific Τ suppression was further examined. This 
revealed that the target of the suppressor Τ cell is а В cell and not a Τ 
helper cell. It was found that the initial encounter between the В cell and 
the Τ suppressor cell is highly specific and relies on the recognition of 
an idiotope located in the variable region of the alpha heavy chain. In 
the suppressed IgA В cell inhibition of the light chain messenger RNA 
could be demonstrated, eventually preventing the expression of both the 
heavy (alpha) and the light chain polypeptides (20). 
As we were able to demonstrate transplacental passage of anti-lgA 
antibodies in the two children of one family, and considering the 
possibility of anti-lgA transmission in the second family, the В cell defect 
and the excessive Τ suppressor function established in the children of 
both families could be the result of similar mechanisms as described 
above. Transplacental anti-lgA antibodies could have generated Τ 
suppressor cells in the children that, in turn, could have down-regulated 
IgA synthesis by an effect on IgA В cells. This hypothesis would explain 
the eventual failure of development of a mature IgA system in patient YT. 
Three of the four children developed anti-lgA antibodies before 
puberty. In a longitudinal survey of 40 children with selective IgA 
deficiency known to our department, only in these three children could 
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anti-lgA antibodies be demonstrated before puberty (PCJ De Laat et al. 
submitted for publication). None of them underwent a transfusion with 
blood or other IgA-containing products that might have induced 
development of anti-lgA antibodies. Our findings indicate a 
predisposition in children from mothers with anti-lgA antibodies to 
develop anti-lgA antibodies before puberty. Furthermore, in these three 
patients and their mothers a concomitant lgG4-lgE deficiency was found 
(Table 5.1). Increased frequencies of anti-lgA antibodies have been 
reported in IgA deficient patients with concomitant IgG subclass and/or 
IgE deficiency (5,6,21,22). In this respect it will be interesting to see 
whether YT will develop anti-lgA antibodies in the near future, as at 
present he has normal serum levels of IgE and lgG4. 
In conclusion, the children investigated in this study appear to form 
a distinct group of patients. Maturation of their IgA system seems to be 
influenced in the perinatal period by maternal anti-lgA antibodies. The 
possibility of induction of IgA-specific excessive Τ suppressor function 
that affects IgA В cell function, and finally results in selective IgA 
deficiency has to be considered. In contrast to all other children with 
selective IgA deficiency known to our department, a tendency was found 
for development of anti-lgA antibodies before puberty in these children. 
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6.1 ABSTRACT 
Three patients with juvenile chronic arthritis treated with aurothioglucose 
developed a significant fall in serum IgA levels. One of them showed 
persistence of IgA deficiency during 3.6 years of chrysotherapy. Serum 
IgA levels after cessation of chrysotherapy remained below the normal 
range in the second patient. In the third patient serum IgA returned to 
pretreatment values. There were no other side-effects, and the incidence 
of infections was not increased. In vitro experiments demonstrated 
diminished IgA В cell function in all 3 patients. At least one of the two 
patients who were still treated with gold at the time the experiments 
were performed had an also diminished IgM В cell function. 
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6.2 INTRODUCTION 
Development of IgA deficiency is a wellknown side-effect of the slow-
acting antirheumatic drugs used In the treatment of adults with 
rheumatoid arthritis. Associations were found with D-penlcillamine (1-3), 
sulfasalazine (4) and gold (1-3,5). Development of IgA deficiency was 
also described in treatment of Wilson's disease with D-penicillamine 
(6,7), of epilepsy with Phenytoin (8,9), and of ulcerative colitis with 
sulfasalazine (10-12). Development of IgA deficiency during 
chrysotherapy In children with juvenile chronic arthritis (JCA) has been 
described (13). The mechanism of drug interference with immunoglobulin 
(Ig) synthesis is largely unknown. 
In this study we report 3 patients with JCA who developed a 
significant fall in serum IgA levels after treatment with aurothioglucose. 
The capacity for in vitro Ig production was studied in pokeweed mitogen 
(PWM)-driven cell cultures. 
6.3 METHODS 
6.3.1 Serum Immunoglobulin measurements 
IgG, IgA and IgM levels were determined by laser-nephelometry using a 
DISC 120 Nephelometer (Hyland, Nivelles, Belgium), and all values were 
calibrated against WHO standard serum No. 67/97. Serum IgA levels 
below the detection limit of the applied nephelometric technique (2 
lU/ml) and, if present, the amount of anti-lgA antibodies were quantita-
ted with a solid-phase radioimmunoassay (14). Saliva IgA levels were 
determined with a radioimmunoassay. 
6.3.2 Cell culture experiments 
Cell preparation and cell cultures were performed as described in 
Chapter 3. Briefly, peripheral blood mononuclear cells (PBMC) from 
patients and controls were isolated by density-gradient centrifugation 
and separated into Τ and non-T cell fractions. Τ and non-T cells from 
controls and patients were either autologously recombined or cocultured 
with respective counterpart cells in triplicate PWM-driven cell cultures. 
Each cell culture was also performed with irradiated Τ cells (3000 rads) 
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to eliminate Τ suppressor function (16). IgA and IgM concentrations in 
the culture supernatants were measured by ELISA and expressed as 
nanograms of Ig per ml supernatant. 
6.3.3 Controls 
The controls used in the coculture experiments were 2 healthy laboratory 
workers with normal serum Ig levels and intact in vitro Ig production. 
6.3.4 Calculations 
A one-sided t-test modified according to Satterthwaite was used for 
comparison of certain cell cultures within one patient-control combination 
(TTEST-SAS procedure). The Bonferroni adjustment was applied to de­
termine significance levels for analysis involving multiple comparisons. 
This implied a significance level of p=0.0125 for IgA (four comparisons), 
and p = 0.0100 for IgM (five comparisons). According to the Bonferroni 
principle (the sum of multiple tests) the total level of significance of a 
pathogenic mechanism concluded from the coculture results then will be 
p = 0.05. The conditions to distinguish defective В cell function, excessive 
Τ suppressor function and diminished Τ helper function were set as 
follows (see also Chapter 3): 
Diminished В cell function was concluded if Ig production by 
cocultures of patient non-T cells + control Τ cells (PnonT+CT) was 
significantly lower than Ig production by recombined control non-T + Τ 
cells (CnonT+CT). 
Excessive Τ suppressor function was only concluded if the 
following conditions were all three fulfilled: Ig production by cocultures 
of CnonT + patient Τ cells (CnonT+PT) must be significantly lower than 
Ig production by recombined CnonT+CT; Ig production by cocultures of 
CnonT + irradiated PT (CnonT+PT*) cells must not be significantly 
different from Ig production by CnonT+CT cells; and Ig production by 
cell cultures containing irradiated PT cells must be significantly higher 
than Ig production by cell cultures containing non-irradiated PT cells. 
Diminished Τ helper function was only concluded if the following 
conditions were all three fulfilled: Ig production by cocultures of CnonT 
+ patient Τ cells (CnonT+PT) must be significantly lower than Ig 
production by recombined CnonT+CT; Ig production by cocultures of 
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CnonT + irradiated PT (CnonT+PT*) cells must be significantly lower 
than Ig production by CnonT+CT cells; and Ig production by cell 
cultures containing irradiated PT cells must not be significantly higher 
than Ig production by cell cultures containing non-irradiated PT cells. 
6.4 RESULTS 
6.4.1 Clinical and Immunological findings 
Some data of the patients at the time of the in vitro experiments and the 
longitudinal serum Ig levels are shown in Table 6.1 and Figure 6.1. 
Table 6.1: Data of the three patients at the time of the cell culture experiments. 
PATIENTS 
Age (yrs) 
Sex 
Duration of gold 
therapy (mths) 
Serum Ig levels 
IgA (lU/ml) 
IgG (lU/ml) 
IgM (lU/ml) 
H LA pattern 
1 
6.1 
F 
12 
0.1 
149 
164 
A2 A9 
B40 B15 
Bw6 Bw60 Bw62 
DR2 DR3 
DRW52 
DQw1 DQw2 
2 
17.7 
F 
57* 
27 
139 
85 
A1 
B7 ΒΘ 
Bw6 
DR3 DR5 
3 
15.6 
M 
9 
36 
155 
121 
A2 A9 
B7 B18 
Bw6 
DR1 
DRw6 DRw52 
DQw1 
* = cultures were performed 24 months after cessation of chrysotherapy. 
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Figure 6.1: Longitudinal serum IgG, IgM and IgA levels (in IUI ml) in 3 patients with 
JCA before, during and after treatment with aurothioglucose. 
T0 = start gold therapy. 
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Patient 1 is a girl with seronegative polyarticular JCA since the age 
of 4 years. Gold therapy was started at the age of 5 years, given as 
weekly intramuscular injections of aurothioglucose (1 mg/kg/dose) during 
20 weeks while therapy with non-steroidal anti-inflammatory drugs was 
continued. Depending on the clinical improvement, the gold injections 
were then gradually reduced to every 2, 3, 4, and then every 6 weeks. 
Serum Ig levels before and during treatment with aurothioglucose are 
shown in Figure 6.1. After 5 months of chrysotherapy the serum IgA 
level was found to be very low (0.1 lU/ml) and IgA was undetectable in 
saliva. This patient is still on gold therapy and serum IgA remained 
below 0.1 lU/ml (2 mg/l). Anti-lgA antibodies could not be detected. The 
incidence of infections since the development of selective IgA deficiency 
was not increased. Other aurothioglucose-induced side-effects did not 
occur in the past 3.6 years of chrysotherapy. 
Patient 2 is a girl with seronegative polyarticular JCA since the age 
of 9 years. Treatment with aurothioglucose was started at the age of 10 
years, and discontinued after 57 months because of clinical 
improvement. She had normal adult values of serum IgA, IgG and IgM 
levels before treatment. Serum Ig levels during chrysotherapy were not 
available. There were no obvious aurothioglucose-induced side-effects, 
and the incidence of infections during chrysotherapy or thereafter was 
not increased. Serum Ig levels after cessation of chrysotherapy are 
shown in Figure 6.1. Three months after the gold injections were 
stopped the serum IgA level was found to be 7 Ill/ml. Later on, IgA 
levels increased gradually but remained below -2SD for the age-specific 
normal values. 
Patient 3 is a boy with systemic-onset JCA since the age of 12 
years. Because of severe polyarticular arthritis aurothioglucose injections 
were started at the age of 14 years when systemic symptoms such as 
fever and rash were already absent since a longer period. Gold therapy 
was discontinued after 9 months because of insufficient clinical effect. 
Serum Ig levels before, during and after treatment with aurothioglucose 
are shown in Figure 6.1. After 4 months of chrysotherapy the serum IgA 
level was found to be 9 lU/ml, gradually increasing to 36 lU/ml just 
before the gold injections were stopped. Serum IgA levels returned to 
pretreatment values after cessation of chrysotherapy (Figure 6.1). There 
were no other aurothioglucose-induced side-effects, and the incidence of 
infections was not increased. 
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6.4.2 In vitro experiments 
In vitro IgA production (Table β.2): 
In all 3 patients a diminished В cell function was established for in vitro 
IgA production. In patients 2 and 3 cocultures of patient non-T + control 
Τ cells (PnonT+CT) produced significantly lower amounts of IgA 
compared to the IgA production by recombined control non-T + Τ cells 
(CnonT+CT). In patient 1 the IgA production resulting from co-culturing 
PnonT+CT cells probably was due to residual В cells in the CT cell 
fraction. This was proven by the fact that IgA production could no 
longer be detected if CT cells were irradiated prior to coculture 
(PnonT+CT*), so preventing Ig production by residual В cells. 
In all 3 patients in vitro IgA production by cocultured control non-T 
+ patient Τ cells (CnonT+PT) was not significantly lower than IgA 
production by recombined CnonT+CT cells, indicating that there was no 
gross abnormality in patients' Τ cell regulatory functions for in vitro IgA 
production. 
In vitro IgM production (Table 6.2): 
In patients 1 and 3 cocultures of PnonT+CT cells resulted in significantly 
decreased amounts of IgM production compared to recombined 
CnonT+CT cells. This could indicate a diminished capacity of these 
patients' В cells for in vitro IgM production, although at the time the cell 
cultures were performed their serum IgM levels were normal (Table 6.1). 
In a previous experiment in vitro IgM production by recombined non-T 
and Τ cells in healthy controls showed considerable inter-individual 
variation ranging from 683-17,243 (mean 6869) ng IgM per ml (Chapter 
4). Regarding the cocultures containing patient non-T cells in the 
present experiments only in patient 1, but not in patient 3 in vitro IgM 
production was certainly lowered (Table 6.2). In patient 2 in vitro IgM В 
cell function was normal. 
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In vitro IgM production by cocultured CnonT+PT cells was not 
significantly lower than IgM production by recombined CnonT+CT cells 
in patients 1 and 2. In patient 3 this comparison revealed a significantly 
(p < 0.01) lower IgM production, and a substantial increase in in vitro 
IgM production was noted in the cultures containing irradiated Τ cells. 
This could suggest presence of excessive Τ suppressor function, but not 
all conditions set for excessive Τ suppressor function (see Methods 
section) were fulfilled. 
Table 6.2: In vitro IgA and IgM production in cultures containing cells of healthy 
controls and/or patients expressed as nanograms of Ig per ml culture 
supernatant (mean ± SO). 
IN VITRO IgA PRODUCTION (ng/cnl) 
CnonT+CT CnonT+CT* CnonT+PT CnonT+PT* PnonT+PT PnonT+PT* PnonT+CT РпопТ+СТ* 
Patient 1 
752 t 176 965 t 166 304 ± 18 272 ±164 <10 <10 344 ± 54 <10 
Patient 2 
1156 t 78 1729 t 265 1253 ±153 1271 ±260 170 ± 29 465 ± 74 240 ± 53 446 ± 103 
Patient 3 
2640 t 266 2914 ± 320 1914 ±239 2860 ±407 117 ± 1 4 737 ±136 266 ± 59 823 ± 34 
IN VITRO IgM PRODUCTION (ng/ml) 
CnonT+CT CnonT+CT* CnonT+PT CnonT+PT* PnonT+PT PnonT+PT* PnonT+CT PnonT+CT* 
Patient 1 
4318 t 882 6408 ± 586 1907 ± 78 5611 ±2272 46 ± 21 226 ±104 480 ±199 154 ± 37 
Patient 2 
7071 ±1632 12240 ± 898 3657 ±715 9729 ± 981 2082 ±399 4917 ±780 2610 ±846 3387 ±1188 
Patient 3 
3577 ± 302 8691 ±1124 1242 ±417 7750 ±1821 1492 ± 33 9027 ±521 1633 ±338 9992 ±1058 
С - control Ρ - patient nonT - non-T celle 
Τ = Τ cells Τ* = 3000 rad Irradiated Τ cells 
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6.5 DISCUSSION 
The influence of aurothioglucose therapy on IgA levels was rather 
heterogeneous. One patient developed persistent nearly undetectable 
IgA levels in serum and saliva. The second patient was found to have a 
very low serum IgA level after 57 months of chrysotherapy. Although a 
gradual increase was noted, IgA levels remained below the normal 
values. This is in accordance with previous studies that reported 
persistence of low to very low serum IgA levels after treatment with 
slow-acting anti-rheumatic drugs (1,2,5,10,13). In the third patient serum 
IgA levels began to rise while he was still receiving gold injections. The 
clinical effect of gold therapy was poor, and probably the rise in serum 
IgA levels is a reflection of his increased rheumatic activity. 
An association between toxic side-effects of gold compounds and 
certain HLA antigens (mainly B8 and DR3) has been described (17-19). 
Van Riel et al. suggested a possible association between lowered serum 
IgA concentrations and susceptibility to aurothioglucose-induced toxic 
effects (19). Wijnands found no differences in saliva IgA levels between 
toxic and non-toxic patients with rheumatoid arthritis treated with gold 
(20). In spite of the decrease in serum IgA levels in our small group of 3 
patients, toxic effects of aurothioglucose were not observed. A common 
HLA pattern could not be established, and only one patient had B8 DR3. 
The mechanism by which aurothioglucose or other slow-acting anti­
rheumatic drugs influence the IgA system remains obscure. Disturbances 
in Ig synthesis at the Τ cell level have been reported (1,5,21). Our in 
vitro Ig production experiments revealed a diminished IgA В cell function 
without evidence for concomitant disturbances of Τ cell regulatory 
functions in all 3 patients. In addition, an also diminished capacity for in 
vitro IgM production was established with certainty in one of the 
patients. The coculture studies showed diminished IgM В cell function in 
two patients. In one of them this was somewhat less pronounced, 
possibly to be explained by his increased rheumatic activity. However, in 
contrast with patient 2, both these patients were still on chrysotherapy 
at the time the cell cultures were performed. Therefore, interference of 
aurothioglucose with in vitro IgM В cell function too seems possible. 
IgA deficiency can be the cause of increased susceptibility to 
infections, especially respiratory tract infections (22,23). In our 3 patients 
however, no increased incidence of infections was noted. In a previous 
study of 22 children with primary selective IgA deficiency we have found 
that additional disturbances in in vitro IgM production may result in more 
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serious clinical manifestations (Chapter 5). One of the patients in the 
present study (patient 1, Table 6.2) definitely had defective in vitro IgM 
production. However, besides JRA she had no other complaints. 
In conclusion, treatment of JCA with aurothioglucose can result in 
decreased serum Ig levels, especially of IgA. In vitro studies in our 
patients revealed diminished В cell functions. Toxic side-effects of 
aurothioglucose were not observed and the rate of infections was not 
increased. 
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Chapter 7 
IMMUNOGLOBULIN LEVELS DURING FOLLOW-UP OF CHILDREN 
WITH SELECTIVE IgA DEFICIENCY. 
P.C.J, de Laat, C.M.R. Weemaes, J.A.J.M. Bakkeren. 
Department of Pediatrics 
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The Netherlands 
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7.1 ABSTRACT 
Longitudinal serum immunoglobulin levels were studied in 36 children 
with selective IgA deficiency during a median follow-up period of 5 
years. Twentyfive children were "sporadic" cases, and 11 were "familial". 
Serum and saliva IgA levels in 23 children remained below 2 mg/l. Eight 
children with IgA levels above 2 mg/l showed considerable intra-
individual variance in serum IgA, but remained IgA deficient. Five 
children at various ages developed IgA levels above 50 mg/l with 
detectable secretory IgA in saliva. In most of the children IgG subclass 
levels were found to be rather high, also at younger ages. 
There were no obvious differences between "sporadic" and "familial" 
cases except an association between IgD deficiency and serum IgA 
levels below 2 mg/l, and between serum levels of IgD above 1 lU/ml and 
of IgA above 2 mg/l, that was found to be significant in the "sporadic" 
group, but not in the "familial" group. 
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7.2 INTRODUCTION 
Selective IgA deficiency is the most frequent primary immunodeficiency 
(1-3). Clinical manifestations are heterogeneous, and vary from none at 
all to associations with auto-immune disease, recurrent infections, and 
atopic disease (1-4). Familial occurrence of selective IgA deficiency with 
various patterns of inheritance has been reported (4-5), but most 
patients described represent sporadic cases. 
Concomitant deficiencies of one or more IgG subclasses, IgD and/or 
IgE have been reported in IgA deficient individuals (6-10). Serum IgA 
levels are not constant, and even at levels below 0.5 mg/l significant 
fluctuations were noted (11). Several cases of transient IgA deficiency 
have been found in follow-up studies (4,12). However, most data on 
serum immunoglobulin levels in patients with selective IgA deficiency are 
derived from cross-sectional studies in selected populations. 
In this study we report longitudinal immunoglobulin levels in a 
group of 36 children during a median follow-up period of five years. 
7.3 PATIENTS AND METHODS 
7.3.1 Patients 
IgA deficiency was defined according to Hong and Ammann (2): serum 
IgA level below 50 mg/l, normal serum IgG and IgM levels, and no or at 
most mild abnormalities of Τ cell function. Diagnosis was only made 
after the age of one year. Sibs and parents of twenty-five children had 
normal serum IgA levels, and these children were designated as 
"sporadic". The remaining eleven children represent cases of "familial" 
IgA deficiency. The clinical manifestations in our patients have been 
reported previously, and mainly consisted of mild respiratory tract 
infections (13). 
The median age at diagnosis was 5.4 years (range 1 to 16). The 
median follow-up period was 5 years (range 2 to 10). Out-patient follow-
up visits took place at least 2-3 times yearly, serum immunoglobulin 
levels were measured, and all patients were checked for development of 
anti-lgA antibodies. In 32 children secretory IgA was measured in saliva 
once or twice. 
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7.3.2 Methods 
IgG and IgM levels in serum and saliva were measured by a single radial 
immunodiffusion according to Van Munster et al. (14) or by laser-
nephelometry. All values were calibrated against WHO standard serum 
No. 67/97. Age and sex specific reference values have been determined 
in an earlier study (15). 
IgA levels in serum and saliva (and if present the amount of class-
specific anti-lgA antibodies) were measured by a titration-
radioimmunoassay as described previously (16). In normal controls 
(n = 13) the mean IgA level in saliva was 35 mg/l (SD 10, range 15-48 
mg/l). IgG subclass levels were measured by radial immunodiffusion and 
calibrated against reference serum containing IgG, 6.2 g/l; lgG2 2.4 g/l; 
IgG, 0.64 g/l and lgG4 0.46 g/l (HOO-020, The Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service). IgG,, IgG, and IgG, 
levels were compared to the age related normal values described by 
Plebani et al. (17). Values below the third percentile (P,) were 
considered as an indication of deficiency of the respective IgG subclass. 
Due to the very broad spread in childhood, reference values for lgG4 are 
not available, and IgG,, deficiency is difficult to define (17). In our study 
an arbitrary level of 0.046 g/l was chosen to delineate at least very low 
levels, probably indicating concomitant lgG4 deficiency. 
Serum IgD levels were measured by ELISA and serum IgE levels by 
radioimmunoassay. Levels below the detection limits (1 and 5 lU/ml, 
respectively) were considered as an indication for IgD or IgE deficiency. 
Serum IgE was designated as "high" if measurements were above +1 SD 
of the reference values provided by Kjellman (18). 
7.4 RESULTS 
7.4.1 Serum Immunoglobulins 
IgA was detectable in very small amounts in serum of all patients except 
an 18-year-old girl who was the only patient with circulating class-
specific anti-lgA antibodies. During the follow-up period IgA levels in 23 
of our patients remained below 2 mg/l. One of them initially had IgA 
levels around 50 mg/l while she suffered from lymphadenitis. Within 2 
months IgA levels declined to below 2 mg/l. 
108 
Considerable fluctuations in serum IgA levels were found in 8 children, 
but all remained IgA deficient (Figure 7.1). The relative elevations of 
serum IgA in these patients were not related to periods with an 
increased rate of infections. Associations between longitudinal serum IgA 
levels and longitudinal serum levels of IgG or IgM could not be 
established. In 5 children serum IgA levels rose above 50 mg/l, but none 
of them attained the lower range of age and sex specific reference 
values (Figure 7.2). 
IgA (mg/1) 
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Figure 7.1: Longitudinal course of serum IgA levels in 8 children with fluctuating 
serum IgA levels. 
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Figure 7.2: Longitudinal course of serum IgA levels in 5 children who developed 
serum IgA levels above 50 mg/l during the follow-up period (Patients 
CW, HB and ТВ are 'sporadic', DF and MJ are 'familial' cases). The 
drawn line represents the P3 percentile for serum IgA levels of healthy 
Dutch school children obtained in an earlier study (15). 
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Longitudinal IgD levels were below 1 ID/ml in 15 children, and 12 of 
them had serum IgA levels below 2 mg/l. IgD levels were above 1 ID/ml 
in 13 children, and 10 of them had serum IgA levels above 2 mg/l. 
The relationship observed between longitudinal serum IgA and IgD levels 
was statistically significant (p=0.007, Fisher test) in the "sporadic" 
group, but not in the "familial" group (Table 7.1). 
Three patients developed undetectable IgD levels during follow-up. IgA 
levels in one of them were always below 2 mg/l. The other two patients 
initially developed IgA levels above 50 mg/l. Later on, coinciding with a 
drop in IgD levels to undetectable values, maturation of their IgA system 
seemed hampered (CW and DF, Figure 7.2). One of the "familial" 
patients (PD, Figure 7.1) demonstrated IgD deficiency during the entire 
follow-up period while IgA levels remained around 20 mg/l. In 7 children 
with variable IgA levels (above 2 mg/l) and in 3 children with serum IgA 
levels above 50 mg/l, IgD levels were above 1 lU/ml (Table 7.1). 
Table 7.1: Longitudinal serum IgA and IgD levels In 2Θ children with selective IgA 
deficiency (8 children were excluded because of insufficient data for IgD). 
IgD 
<1 lU/ml >1 lU/ml 
Sporadic (n = 17) 
<2 mg/l 9 1 
IgA ρ = 0.007 
>2 mg/l 1 6 (Fisher test) 
Familial (n=11) 
<2 mg/l 3 2 
IgA not significant 
>2 mg/l 2 4 
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IgE levels below 5 lU/ml were found in 10 children (8 "sporadic" and 
2 "familial"). In 5 of the "sporadic" patients serum IgE became below 5 
lU/ml during follow-up. Eleven children (5 "sporadic" and 6 "familial") 
demonstrated high levels of IgE. There was no consistent association 
between height of serum IgE and atopic complaints. Three "sporadic" 
patients had atopic complaints despite IgE levels below 5 lU/ml, and in 
two of them RAST tests for specific IgE (Phadiatop, Pharmacia 
Diagnostics BV, Woerden, The Netherlands) were positive. Six out of the 
11 children with high IgE levels showed positive RAST tests for specific 
IgE, and 4 of them had atopic complaints. 
Serum IgG levels were elevated significantly in both "sporadic" and 
"familial" patients, with already elevated levels at younger ages (13). 
Longitudinal IgM levels were within or just above the normal range. 
Longitudinal IgG subclass levels were studied in 34 patients (Figure 7.3). 
The increase in serum IgG levels was not found to be due to elevated 
concentrations of a specific IgG subclass. Particularly in the "familial" 
group, several patients demonstrated already (very) high IgGj levels at 
young ages (Figure 7.3). Concomitant lgG2-lgG4 deficiency was found in 
two boys both belonging to the "sporadic" group. One was a mentally 
retarded child with ring chromosome 22 but no other complaints. The 
other boy had considerably lowered serum IgG levels. During follow-up 
his serum IgG and IgM levels further declined, and he was considered to 
be a case of late-onset hypogammaglobulinaemia (13). In one patient 
lgG2 levels were low at first, but increased during follow-up (Figure 7.3). 
His lgG4 levels were very high (above 3 g/l). Undetectable lgG4 levels 
alone were noted in 5 children (4 "sporadic" and 1 "familial"). 
Figure 7.3: Longitudinal course of IgG subclass levels in 32 children with selective 
IgA deficiency. Age specific reference values (3rd percentile curve, 
expected value determined using regression analysis, and 97th 
percentile curve) for /gG,, /gG2 and lgG3 are according to Plebani et al. 
(17). The right axis refers to the percentage of the reference serum. 
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7.4.2 IgA In saliva 
Secretory IgA was measured once or twice in saliva of 32 children. If 
serum IgA levels were below 2 mg/l, saliva IgA levels were also below 2 
mg/l in all patients. Saliva IgA measurements in children with longitudinal 
serum IgA levels above 2 mg/l are shown in Table 7.2. In the children 
with serum IgA levels increasing above 50 mg/l, IgA was also detectable 
in saliva (Figure 7.2, Table 7.2). 
Table 7.2: Saliva IgA in children with serum IgA levels above 2 mg/l. 
IgA 
Patient 
sporadic 
R.vdB. 
E.D. 
M.vdB. 
V.P. 
C.W. 
H.B. 
T.B. 
familial* 
T.M. 
P.D. 
T.J. 
D.F. 
M.J. 
age 
(yrs) 
1 
2 
8 
10 
4 
4 
6 
1 
4 
7 
5 
7 
1st Sample 
serum 
(mg/l) 
14 
8 
20 
20 
31 
23 
32 
7.6 
11.7 
2.2 
45.1 
7.0 
saliva 
(mg/l) 
<2 
β 
< 2 
< 2 
< 2 
6.6 
< 2 
< 2 
4.2 
<2 
3.7 
< 2 
age 
(yrs) 
6 
8 
11 
9 
14 
9 
13 
15 
2nd Sample 
serum 
(mg/l) 
2.3 
19 
19 
112 
380 
21.2 
6.9 
75 
saliva 
(mg/l) 
< 2 
32 
11.1 
39 
139 
41.1 
3.5 
86 
= patient Ba.B. (Figure 7.1) was not tested for saliva IgA. 
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7.5 DISCUSSION 
In patients without anti-lgA antibodies serum IgA was always detectable 
if measured by a sensitive radioimmunoassay, but most children 
demonstrated persistence of very low levels (<2 mg/l). Although still 
within the range set for definition of IgA deficiency (<50 mg/l), in some 
patients considerable intra-individual variance was noted. These findings 
are in agreement with Laschinger et al. who, in order to establish an IgA 
deficient blood donor panel, still found considerable fluctuations in 
serum IgA concentrations even below a level of 0.5 mg IgA/l (11). The 
fluctuations in serum IgA levels found in some of our patients were not 
related with infectious episodes and there were no simultaneous 
fluctuations in serum IgG or IgM levels. Studies on IgA heavy chain 
constant region genes (situated on chromosome 14) have revealed that 
there are no structural deletions in individuals with selective IgA 
deficiency (19). The underlying cause of IgA deficiency generally is 
considered to be a disturbance in the regulation of В cell differentiation 
to IgA-secreting plasma cells (20-22). Supposing that these regulatory 
disturbances are not constant in all patients, this could explain why in 
some patients fluctuating IgA levels can be found. 
Five children developed serum IgA levels above 50 mg/l and IgA 
was also detectable in saliva, but during the available follow-up period 
none of them attained the lower range of age and sex specific reference 
values. However, if IgA levels will continue to rise, perhaps these 
patients will represent cases of transient IgA deficiency as reported 
previously (4,12). It has to be noted that in our study maturation of the 
IgA system still occurred at relatively advanced ages. This is in contrast 
with Plebani et al. who found that IgA deficiency in children with IgA 
levels below 50 mg/l generally is persistent (23). 
In agreement with the elevation of longitudinal IgG levels in our 
patients (13), longitudinal IgG subclass levels (including IgGJ in most of 
our patients, suffering from only relatively mild infections, generally were 
found to be rather high. Elevated IgG subclass levels in selective IgA 
deficiency have been described by Klemola (8), but most of these 
patients were suffering from active diseases (juvenile chronic arthritis 
and coeliac disease). One of our patients developed late-onset 
hypogammaglobulinemia. Recently a common susceptibility gene located 
in the MHC class III region on chromosome 6 has been implicated for 
both selective IgA deficiency and common variable immunodeficiency, 
suggesting that these are related disorders (22,24). 
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In the "sporadic" group but not in the "familial" group, a statistically 
significant association between IgD deficiency and serum IgA levels 
below 2 mg/l, and between detectable serum IgD and serum IgA levels 
above 2 mg/l was found. Two children with serum IgA levels above 50 
mg/l, who thusfar did not fully mature to normal IgA levels, developed 
IgD deficiency in the same period. Concomitant IgD deficiency in 
individuals with IgA deficiency has been reported previously (7,10). The 
role of IgD in the regulation of the immune response is not clear as yet. 
In a sequence of studies by Coico and coworkers an immuno-
augmenting effect of IgD in both primary and secondary responses has 
been described in the murine system (25). Injection of myeloma-derived 
IgD caused an increase in the numbers of IgA- and lgG2-producing 
spleen cells. It was shown that the immuno-augmenting effect of IgD was 
Τ cell-dependent (25). Τ cells with receptors for IgD (T-delta cells) 
involved in the humoral immune response have also been demonstrated 
in humans (26). The relation between longitudinal IgA and IgD levels in 
our patients could suggest an immunoregulatory role for IgD in the 
development of a mature IgA system. The difference observed in IgA 
and IgD levels between both groups then would be supportive for a 
difference in the mechanism causing IgA deficiency in "sporadic" and 
"familial" patients. However, another explanation for the relation observed 
between IgA and IgD levels to be considered would be that both are 
influenced by a common mechanism regulating В cell differentiation. 
In conclusion, apart from the statistically significant association 
observed between longitudinal serum IgA and IgD levels in the 
"sporadic" group, there were no differences in longitudinal 
immunoglobulin levels between the "sporadic" and "familial" cases of 
selective IgA deficiency presented in this study. 
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Chapter 8 
DISCUSSION AND CONCLUDING REMARKS 

8.1 CLINICAL MANIFESTATIONS 
Clinical manifestations were studied longitudinally in the two groups of 
"sporadic" and "familial" cases with selective IgA deficiency. All patients 
had undetectable or extremely low levels of secretory IgA in saliva. The 
majority of the children of both groups suffered from recurrent 
respiratory tract infections (RRTI), especially recurrent otitis media. There 
were no differences between "sporadic" and "familial" cases. Infection 
episodes generally followed a mild course and, although RRTI were more 
frequently found in early childhood, also at older ages RRTI often 
occurred. In this way the incidence of RRTI was not merely a reflection 
of age, comparable to healthy children, but appeared to be really 
increased. Furthermore, the 12 children who were not referred because 
of complaints also demonstrated RRTI during follow-up. From these 
findings it was concluded that in both patient groups there was a clear 
association between selective IgA deficiency and RRTI (Chapter 2). 
IgG subclass deficiencies (mainly IgG.,) are known to predispose to 
more frequent and severe respiratory tract infections (1). Only two 
children had concomitant lgG2-lgG4 deficiency: both were "sporadic" 
cases, one child was asymptomatic, the other developed late onset 
hypogammaglobulinemia (patients PM and PN in Chapter 2). Isolated 
IgG., deficiency was not found. Isolated lgG4 deficiency was found in 8 
(20%) IgA deficient children (4 of each group). Clinical symptoms in 
lgG4-lgA deficient patients were not different from those in IgA deficient 
patients without concomitant IgG, deficiency. The percentage found for 
IgG« deficiency was similar to the percentage reported for the normal 
population (2). Longitudinal IgG but not IgM levels were elevated 
significantly in both groups, and all IgG subclasses contributed to this 
elevation (Chapter 7). In accordance with recent reports (3,4), in young 
children with selective IgA deficiency a tendency was noted for high IgG 
subclass levels. Whether the elevated IgG levels must be regarded as a 
compensatory mechanism for IgA deficiency, or merely are a reflection 
of frequent infections remains a difficult question. It has been reported 
that the immune response after oral cholera vaccination, in normal 
individuals predominantly of the IgA class, in symptomatic IgA deficient 
patients was often of the IgG class (5). 
The relation was studied between the clinical manifestations 
observed in both patient groups and the pathogenic mechanism found 
responsible for defective in vitro IgA production (Chapter 4). In a small 
number of children diminished Τ helper function was found for both in 
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vitro IgA and IgM production. If this in vitro phenomenon forms a correct 
reflection of the in vivo immune status, these children could have a more 
severe immunodeficiency compared to others with selective IgA 
deficiency. Some evidence for this hypothesis could be found in the fact 
that the two children with more severe infections (osteomyelitis and 
recurrent purulent lymphadenitis) both belonged to this group (Chapter 
4). Furthermore, it was found that clinical symptoms other than RRTI or 
atopic disease mainly were recorded in patients who also had 
disturbances in in vitro IgM production. The heterogeneity of clinical 
manifestations in selective IgA deficiency could be based on the fact 
that some patients tend to develop more general disturbances in the 
regulation of immunoglobulin synthesis and consequently have more 
complaints. One patient who had severe RRTI and an episode of 
Haemophilus influenzae meningitis developed common variable 
immunodeficiency (CVID) during the follow-up period (Chapter 2). In the 
3 patients with gold-induced decreases in serum IgA levels no increased 
rate of infections was observed, although at least one of them also had 
a disturbance in in vitro IgM production (Chapter 6). 
A difference between both groups was noted in the occurrence of 
atopic complaints (Chapter 2). Only in the "sporadic" group a high 
incidence was found, so it appeared that allergic states are more 
frequently encountered in "sporadic" cases of selective IgA deficiency. It 
is clear that a definite conclusion In this matter requires a study of two 
much larger groups of "sporadic" and "familial" patients. Follow-up study 
of the longitudinal serum IgE levels in both groups showed that there 
was no association between height of serum IgE levels and the 
occurrence of atopic complaints, nor with the rate of infections. 
Concomitant IgE deficiency was found in 13 children. Elevated IgE levels 
were found in 11 children, but only 6 of them suffered from atopic 
complaints (Chapter 2). Serum IgE levels in individuals with IgA 
deficiency apparently can be elevated independent of the occurrence of 
atopic disease. Research on Τ cell-derived cytokines has revealed that 
¡nterleukin (IL)-4 is not only important for IgA В cell differentiation, but is 
also involved in the pathways towards production of IgG, and IgE (6). 
Perhaps in some individuals with selective IgA deficiency the defect in 
IgA production generates an overproduction of IL-4. This could then 
result in an overshoot of IgE and IgG, production, causing an increase 
in the respective serum levels. 
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Compared to normal individuals elevated IgM and IgG levels have 
been reported in secretions of patients with selective IgA deficiency 
(7,8), but no differences were found between symptomatic and healthy 
IgA deficient individuals (Θ). We investigated saliva IgG and IgM levels 
once or twice in 16 children (10 "sporadic" and 6 "familial" cases). The 
results were heterogeneous: saliva IgG ranged from 13 to 101 mg/l 
(mean 40 mg/l), and IgM from 5 to 122 mg/l (mean 33 mg/l). 
Interpretation was hampered by the facts that the ages at the time of the 
saliva collections varied from 3 to 15 years, and that six of the children 
belonged to the group of patients with variable serum and saliva IgA 
levels. It only could be concluded that the saliva IgG and IgM levels 
found in the patients studied in this thesis appeared to be higher than 
those in the control group reported by Norhagen et al. (8): median IgG 
10.1 mg/l, median IgM 6.3 mg/l. 
In 5 children (3 "sporadic" and 2 "familial" cases) serum IgA levels 
rose above 50 mg/l, and IgA was detectable in saliva (Chapter 7). None 
of them has yet reached the lower range of reference IgA levels. 
However, if serum IgA levels continue to rise they will have to be 
considered as cases of transient IgA deficiency. The frequency of 
respiratory tract infections and atopic complaints was found to decline. 
The follow-up of these children further demonstrated that maturation of 
the IgA system can still occur at relatively advanced ages. This finding is 
in contrast with previous reports, in which was stated that so-called 
severe or absolute IgA deficiency (IgA levels <50 mg/l) usually is 
persistent (9,10). 
8.2 ANTI-lgA ANTIBODIES 
The role of anti-lgA antibodies in the pathogenesis of selective IgA 
deficiency is not fully understood. Several studies have reported a 
higher frequency of mother-to-child inheritance of selective IgA 
deficiency than of father-to-child inheritance (11-13). It has been 
suggested that transplacental passage of IgG class anti-lgA antibodies 
could result in IgA deficiency in the infant (14-16). The capability of anti-
lgA antibodies to induce the formation of IgA-specific Τ suppressor cells 
that inhibit IgA production by affecting IgA В cell development has been 
demonstrated in the murine system (17). 
Four children from two families in which IgA deficient mothers had 
circulating class-specific anti-lgA were investigated. In one family 2 
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children were followed from birth: one of them (patient NT) was IgA 
deficient from birth, his younger brother (patient YT) had normal serum 
IgA levels in his first year of life but turned out to be IgA deficient at the 
age of five. In the other family immunoglobulin levels in early childhood 
were not available. The in vitro experiments revealed that in all four 
children В cell defects were indeed combined with excessive IgA-specific 
Τ suppressor function, thus strongly suggesting that IgA deficiency in 
the progeny was the result of maternal anti-lgA antibody-induced 
excessive Τ suppressor function that subsequently had affected IgA В 
cell differentiation (Chapter 5). The findings in patient YT suggested that 
this influence on IgA В cell differentiation apparently was not limited to 
the prenatal period but can still take place a long time after birth and is 
not caused by at that time circulating anti-lgA antibodies. 
Three of the 4 children from IgA deficient mothers with circulating 
anti-lgA antibodies developed anti-lgA antibodies themselves up till now. 
All three children and also their mothers had concomitant lgG4-lgE 
deficiency. Patient NT was IgA deficient from birth, but IgE levels initially 
were normal. At the age of three he became IgE deficient and IgA 
antibodies were first detected. Development of anti-lgA antibodies in this 
distinct group of patients apparently can occur anytime between birth 
and puberty, as in one of the children (patient AL) it was observed only 
at the age of nine. Patient YT had normal levels of serum lgG4 and IgE 
up till now and anti-lgA antibodies could not be detected as yet. 
During the follow-up period of the other 36 children, only in one 
other patient (patient MC, Chapter 2) class-specific anti-lgA antibodies 
could be detected. She was known with lgG4-lgA deficiency and 
developed anti-lgA antibodies at the age of eighteen. At the same time 
she was found to have become IgE deficient. 
Thus, all 6 individuals (4 children and 2 mothers) in this study with 
presence of circulating anti-lgA antibodies had concomitant lgG4-lgE 
deficiency. Increased frequencies of anti-lgA antibodies in IgA deficient 
patients with concomitant IgG subclass and/or IgE deficiency have been 
reported, although the explanation for this association is unknown (18-
20). Development of anti-lgA antibodies before puberty was only found 
in the children from IgA deficient mothers with anti-lgA antibodies. 
Perhaps periodic screening for anti-lgA antibodies in children with 
selective IgA deficiency until puberty should be reserved for cases with 
concomitant IgG subclass and/or IgE deficiency, and for IgA deficient 
children of IgA deficient mothers with circulating anti-lgA antibodies. 
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8.3 PATHOGENESIS OF SELECTIVE IgA DEFICIENCY 
The major cause underlying selective IgA deficiency is thought to be 
defective IgA В cell differentiation and maturation. Although on rare 
occasions structural defects in the alpha heavy chain gene have been 
demonstrated, this never affected both the alpha-1 and alpha-2 gene 
(13). The individuals with these deletions were not totally IgA deficient, 
but lacked either IgA, or lgAa. Our findings that two of the patients who 
possibly had transient IgA deficiency were "familial" cases (patients DF 
and MJ, Chapter 7), and that another "familial" patient (patient HB) had 
an identical twin brother without IgA deficiency also suggested that 
structural gene deletions are not likely to play an important role in 
selective IgA deficiency. Hammarström et al. have reported that in most 
individuals with selective IgA deficiency there were no structural gene 
deletions in the IgA heavy chain constant region genes on chromosome 
14 (21). This has led in general to the conclusion that in IgA deficiency 
there Is a disturbance in the regulation of terminal differentiation of В 
cells to IgA-secreting plasma cells. Up till now the exact mechanisms 
involved In the regulation of IgA synthesis are not clear. Regulatory 
genes for IgA synthesis have been suggested, but have not been 
precisely located as yet. 
The association of selective IgA deficiency with aberrations in 
chromosome 18 is well-known. One of the patients also had presence of 
a ring-chromosome 18 (patient EvdB, Chapter 2). The role of gene 
products of chromosome 18 In IgA synthesis is difficult to interpret 
because IgA deficiency has been associated as well with deletions of the 
short arm (18p-), as with deletions of the long arm (18q-), and with ring-
chromosome 18; possibly multiple loci are involved (13). The other 
patient with a chromosomal abnormality group (patient PM, Chapter 2) 
had a ring-chromosome 22. He belonged to a large family, and none of 
the family members had IgA deficiency. An association between 
aberrations of chromosome 22 and selective IgA deficiency has not been 
reported before. Both patients were mentally retarded and had physical 
abnormalities. Chromosomal analysis was also performed in 14 IgA 
deficient children without mental deficiency and showed no abnormalities 
(22), in accordance with a previous report in which 80 IgA deficient 
individuals were investigated (23). It was concluded that chromosomal 
analysis is only recommendable in IgA deficient individuals with mental 
deficiency or physical abnormalities (Chapter 2). 
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Associations of selective IgA deficiency with particular combinations 
of major histocompatibility complex alleles of all three classes (so-called 
MHC supratypes) have been reported (24-27). These findings suggest 
that genes regulating IgA В cell differentiation could be located within or 
near the MHC complex on chromosome 6. The regulatory disturbance in 
В cell differentiation can be limited to IgA synthesis only, as was the 
case in 14 of the patients who had true "selective" IgA deficiency. 
However, additional deficiencies of other immunoglobulins (IgG 
subclasses, IgD, IgE) are not unusual in patients with selective IgA 
deficiency (3,4,9,28-30), and were also found in the majority of our 
patients (Chapter 7). Furthermore, in families of patients with selective 
IgA deficiency the incidence of other immunoglobulin deficiencies, 
including true hypogammaglobulinemia, is increased (9,31). One of our 
patients developed late onset hypogammaglobulinemia, resembling the 
patient described by Morrei! et al. (32). Perhaps selective IgA deficiency 
forms a more simple representative of a much broader spectrum of 
regulatory disturbances of immunoglobulin synthesis. In vitro studies 
have shown that the immunological disturbances implicated in CVID and 
selective IgA deficiency have a certain resemblance: intrinsic В cell 
defects and/or Τ cell regulatory disturbances. Immunogenetic studies 
focussing on regulatory genes for В cell differentiation have already 
demonstrated that susceptibility to both CVID and selective IgA 
deficiency appears to be determined by genes within or near the major 
histocompatibility complex class III gene region on chromosome 6, 
supporting the hypothesis that these immunodeficiency disorders are 
related (26,27). We cannot comment on this interesting issue as HLA 
typing was not performed in the present study. 
In most of the patients serum IgA levels were studied during a 
prolonged period of time. Although the majority showed persistence of 
very low IgA levels (<2 mg/l), in some children, both "familial" and 
"sporadic", considerable fluctuations were noted (Chapter 7). There was 
no relation with infection episodes, and there were no simultaneous 
fluctuations in other immunoglobulins. Perhaps these fluctuations reflect 
an imbalanced regulation of IgA synthesis. 
The capacity for in vitro IgA production was investigated in 26 
children (in 14 "sporadic" and 8 "familial" cases in Chapter 4; and in 4 
"familial" cases in connection with anti-lgA antibodies in Chapter 5). 
PBMC of all children but one (a child who probably had transient IgA 
deficiency) demonstrated defective in vitro IgA production compared to 
healthy controls. In an early report Waldmann and coworkers described 
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a secretory blockade in IgA plasma cells (14). We also have investigated 
this phenomenon, but none of the patients showed evidence for a 
secretory blockade of IgA. 
The molecular and cellular interactions that regulate the isotype-
specific differentiation of В cells to IgA production and secretion are 
profoundly influenced by Τ cells and Τ cell-derived factors (cytokines) at 
various stages (33). Τ cell abnormalities have been reported in patients 
with selective IgA deficiency (14,34-36). Recent developments in cytokine 
research have allowed the possibility to study the role of interleukins in 
immunodeficiency disorders. IL-5 mRNA producing cells have been 
investigated in individuals with selective IgA deficiency or CVID, and 
revealed no abnormalities compared to healthy controls (37). In patients 
with CVID addition of IL-2, IL-4 and IL-6 to cell cultures had only minor 
effects on immunoglobulin synthesis (38). However, it has to be 
considered that the lymphocyte populations used for in vitro cultures 
possibly do not contain the precursor population that is dependent on 
certain cytokines for differentiation. Defects in the receptors for 
interleukins in the relevant target cell populations have also been 
suggested (37). 
Our in vitro culture experiments emphasized on the cellular basis of 
selective IgA deficiency. Three pathogenic mechanisms could be 
distinguished (Chapter 4): pure defective IgA В cell function, defective 
IgA В cell function with IgA-specific excessive Τ suppressor function, 
and defective IgA В cell function with diminished Τ helper function 
(which was not always IgA-specific). There were no differences in 
pathogenic mechanisms between "sporadic" and "familial" cases. 
Defective in vitro IgA В cell function was found in most of the cases, but 
in 12 out of 22 patients additional Τ cell disturbances could be 
established. This finding agrees well with the current opinion that IgA В 
cell differentiation is influenced at various stages by Τ cells and Τ cell-
derived factors. Pure Τ cell abnormalities were not found in the present 
study. The significance of the additional Τ cell abnormalities remained 
unclear. The question remained whether Τ cell abnormalities (found in 
connection with defective IgA В cell function) represented a primary 
cause or became manifest later on in life. A primary role could not be 
substantiated as in the "familial" cases, although limited in number, a 
consistent pattern of Τ cell disturbances was found in only one of four 
families (Chapter 4). The excessive Τ suppressor function found without 
exception in the children from mothers with anti-lgA antibodies was 
thought to be significant in the pathogenesis of IgA deficiency in this 
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distinct group (Chapter 5). Additional excessive Τ suppressor function 
was also found in another three patients (Chapter 4), but was neither 
related to anti-lgA antibodies nor to clinical manifestations. 
The function of IgD in the human immune system is not exactly 
known. The possibility of an immunoregulatory role of IgD deserves 
attention. IgD deficiency is often found in individuals with selective IgA 
deficiency (9,28,30). In the early stages of В cell development IgD is 
expressed on the surface of В cells and disappears afterwards in the 
process of isotype-switching (Chapter 1). Its role in the isotype-switch is 
unknown. An immuno-augmenting effect of IgD on IgA and lgG2 immune 
responses mediated by Τ cells with receptors for IgD (T-delta cells) has 
been described (39). In our patients in the "sporadic" group a significant 
association was found between longitudinal serum IgD and IgA levels. 
IgD deficiency was associated with serum IgA levels <2 mg/l, and if IgD 
was detectable in serum in most patients IgA levels were >2 mg/l 
(Chapter 7). This could suggest a regulatory role for IgD in IgA 
synthesis. Another possibility could be that IgD and IgA differentiation 
share certain regulatory mechanisms in common. 
Further knowledge on the factors involved in the regulation of the 
process of В cell differentiation towards immunoglobulin-producing 
plasmacells in humans needs to be obtained. The results can be used in 
future experiments investigating the pathogenesis of humoral 
immunodeficiencies including selective IgA deficiency. The role of 
interleukins can be further investigated by measurement of in vitro 
interleukin production in cell cultures, and by evaluating the effects of 
addition of recombinant interleukins to cell cultures on immunoglobulin 
synthesis. Addition of exogeneous IgD to cell cultures of IgA deficient 
individuals, with or without concomitant IgD deficiency, could elucidate 
the immunoregulatory role of IgD assumed in Chapter 7. 
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8.4 GENERAL CONCLUSION 
The aim of this thesis was to see whether the well-known 
heterogeneity of patients with selective IgA deficiency could be lessened 
by dividing our well-documented patients into a "sporadic" and a 
"familial" group. Regarding the clinical follow-up data, the longitudinal 
immunoglobulin levels and the in vitro experiments performed to 
elucidate the pathogenic mechanism, no differences were found between 
the two groups except the more frequent observation of atopic 
complaints and the relation that appeared to exist between longitudinal 
serum IgA and IgD levels in the "sporadic" group. So the heterogeneity 
could not be attributed to differences between "sporadic" and "familial" 
patients. However, we and others have found evidence that selective IgA 
deficiency and CVID appear to be related disorders. The heterogeneity 
of selective IgA deficiency could then be explained by the assumption 
that some patients with selective IgA deficiency tend to shift towards 
development of CVID and have more and more severe complaints (for 
instance more severe infections or autoimmunity), while others who 
remain relatively asymptomatic do not. 
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SUMMARY 
Selective IgA deficiency was first described some 30 years ago and is 
considered to be the most frequent primary immunodeficiency. Many 
reports have been published describing various clinical and 
immunological aspects of this immunodeficiency state. It is concluded in 
almost all studies that individuals with selective IgA deficiency form a 
heterogeneous population. 
The aim of this thesis is an effort to lessen this heterogeneity by 
studying a well-defined and longitudinally documented population of 
children and adolescents with selective IgA deficiency, dividing them into 
two groups of "sporadic" and "familial" cases. 
Chapter 1 describes the structure and function of IgA, followed by a 
brief review of the main clinical and immunological aspects of selective 
IgA deficiency. The current knowledge on the process of В cell 
differentiation towards IgA secreting plasma cells and the literature upon 
the pathogenesis of selective IgA deficiency is summarized. 
Chapter 2 describes longitudinally the clinical manifestations in 25 
"sporadic" and 15 "familial" patients with selective IgA deficiency. There 
were no obvious differences between "sporadic" and "familial" cases. The 
majority of both groups had frequent respiratory tract infections, 
especially recurrent otitis media. Atopic complaints were also frequently 
found and occurred more often in the "sporadic" group. The frequency 
of atopic complaints was not well related with the height of serum IgE 
levels. Chromosomal abnormalities (ring 18 and ring 22) were only found 
in the two IgA deficient children who also were mentally retarded. 
Concomitant IgG subclass deficiencies were not frequent in the two 
groups. The longitudinal serum IgG levels were elevated significantly in 
both groups, probably reflecting the increased rate of infections. Anti-
IgA antibodies were found in 4 patients, 3 of them had an IgA deficient 
mother with circulating class-specific anti-lgA antibodies. All 4 patients 
had concomitant IgG^lgE deficiency. 
Chapter 3 introduces the pokeweed mitogen-driven cell culture system 
for in vitro immunoglobulin production used in this thesis to investigate 
the cellular basis of selective IgA deficiency. Statistical comparisons of 
the amounts of in vitro immunoglobulin production in cocultures of 
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counterpart non-T and Τ cell fractions of patients and healthy controls 
enabled the distinction of defective В cell function, excessive Τ 
suppressor function and diminished Τ helper function. The methods and 
statistical calculations are described. 
Chapter 4 describes the results of in vitro immunoglobulin production in 
22 children with selective IgA deficiency (14 "sporadic" and 8 "familial") 
in relation to the clinical manifestations. All patients but one had 
defective in vitro IgA production. In 4 children also in vitro IgM 
production was diminished. The coculture studies revealed that all but 
one had а В cell defect for in vitro IgA production. So in this study it 
was found that the pathogenic base of selective IgA deficiency at a 
cellular level was defective IgA В cell function. In 12 patients additional Τ 
regulatory disturbances were found. Three had IgA-specific excessive Τ 
suppressor function. Diminished Τ helper function was found in 4 
patients for in vitro IgA production, while 5 patients had diminished Τ 
helper function for both in vitro IgA and IgM production. There were no 
obvious differences between "sporadic" and "familial" cases. The 
importance of the role of additional Τ cel regulatory disturbances in the 
pathogenesis of selective IgA deficiency is not clear. There were no 
differences in clinical manifestations between patients with a pure В cell 
defect and patients with а В cell defect and additional IgA-specific Τ cell 
regulatory disturbances. It was noted that most of the patients with more 
severe infections or with complaints other than recurrent respiratory tract 
infections or atopy also had disturbances in in vitro IgM production. 
Perhaps these patients have a more serious immunodeficiency shifting 
towards the development of common variable immunodeficiency. This 
hypothesis could be an explanation for the heterogeneity observed in 
patients with selective IgA deficiency. 
Chapter 5 describes the results of the in vitro immunoglobulin 
production experiments in 4 "familial" children with selective IgA 
deficiency. They belonged to two families in which the mothers were IgA 
deficient and had circulating class-specific anti-lgA antibodies. In one of 
the families transplacental passage of maternal anti-lgA has been 
demonstrated. It has been suggested in the literature that in some 
patients with selective IgA deficiency the maturation of the IgA system is 
influenced in the perinatal period by maternal anti-lgA antibodies, but 
the mechanism remains unclear. The coculture experiments in our 
patients showed that all four children had an IgA В cell defect with 
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additional IgA-specific excessive Τ suppressor function. We suggest that 
in these children transplacental anti-lgA has generated IgA-specific Τ 
suppression that finally affected IgA В cell function. This latter process is 
not limited to the perinatal period as one of the children became IgA 
deficient after the age of one year. Three of the children developed anti-
lgA antibodies at various ages but before puberty. 
Chapter 6 describes 3 patients with juvenile chronic arthritis who 
developed a significant fall in serum IgA levels after treatment with 
aurothioglucose. One of them developed persistent "true" selective IgA 
deficiency and is still treated with gold. In the second patient serum IgA 
levels remained below the normal range after cessation of gold therapy. 
In the third patient serum IgA levels returned to pretreatment values. 
None of the patients had toxic side-effects and the rate of infections was 
not increased. In vitro immunoglobulin production experiments showed 
that all three had diminished IgA В cell function. At least one of the two 
patients who were still on gold therapy at the time the experiments were 
performed had an also diminished IgM В cell function, although serum 
IgM levels were in the normal range in both. 
The conclusion of the in vitro experiments was that aurothioglucose can 
interfere with in vitro В cell function. Sometimes this apparently can 
cause a significant fall in serum immunoglobulin levels, especially of IgA. 
In contrast with most patients with primary selective IgA deficiency this 
caused no symptoms in our 3 patients. 
Chapter 7 describes the longitudinal immunoglobulin levels in 36 
children with selective IgA deficiency (25 "sporadic" and 11 "familial"). 
In the majority serum and saliva IgA levels remained below 2 mg/l. 
Considerable variance in serum IgA levels was noted in 8 children, but 
they all remained IgA deficient. Five children developed serum IgA levels 
above 50 mg/l at various ages, and IgA was detectable in saliva. They 
could represent cases of transient IgA deficiency, but none of them has 
reached the lower range of the normal values as yet. Most of the 
children demonstrated rather high IgG subclass levels, also at younger 
ages. There were no obvious differences in immunoglobulin levels 
between "sporadic" and "familial" cases except an association between 
IgD deficiency and serum IgA levels below 2 mg/l, and between serum 
levels of IgD above 1 lU/ml and of IgA above 2 mg/l, that was found to 
be significant in the "sporadic" group, but not in the "familial" group. 
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This could suggest an immunoregulatory role of IgD in the process of 
IgA В cell differentiation. 
Chapter 8 finally provides a general discussion of the clinical and 
immunological findings in the two groups of patients, followed by some 
directions for future research. 
It was concluded that there were no obvious differences between 
"sporadic" and "familial" patients. Anti-lgA antibodies could be 
demonstrated in 6 patients (4 children and 2 mothers) and they all had 
concomitant lgG4-lgE deficiency. Development of anti-lgA antibodies 
before puberty was only found in the children of IgA deficient mothers 
with anti-lgA antibodies. Considering the findings in this thesis, selective 
IgA deficiency is based on (regulatory) disturbances in В cell 
differentiation. In some patients this is restricted to IgA, but others have 
more general disturbances that can concern other immunoglobulins. The 
assumption that selective IgA deficiency forms one side of a broader 
spectrum of disturbances in immunoglobulin synthesis with on the other 
side common variable immunodeficiency, would be a reasonable 
explanation for the heterogeneity observed in patients with selective IgA 
deficiency. 
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SAMENVATTING 
Selectieve IgA deficiëntie is 30 jaar geleden voor het eerst beschreven 
en wordt beschouwd als de meest frequent voorkomende primaire 
immuundeficiëntie. Er zijn vele publicaties verschenen over allerlei 
klinische en immunologische aspecten van deze immuundeficiëntie. Een 
belangrijke conclusie uit bijna alle studies is dat individuen met 
selectieve IgA deficiëntie een heterogene populatie vormen. 
Het doel van dit proefschrift is een poging om deze heterogeniteit 
te verminderen door een goed gedefinieerde en longitudinaal vervolgde 
populatie van kinderen en adolescenten met selectieve IgA deficiëntie te 
bestuderen, onderverdeeld in twee groepen: "sporadische" en "familiaire" 
patiënten. 
Hoofdstuk 1 beschrijft de structuur en functie van IgA, gevolgd door 
een kort overzicht van de belangrijkste klinische en immunologische 
aspecten van selectieve IgA deficiëntie. Een samenvatting van de huidige 
kennis over het proces van В cel differentiatie tot IgA secreterende 
plasmacellen en de literatuur over de mogelijke Pathogenese van 
selectieve IgA deficiëntie besluit het hoofdstuk. 
Hoofdstuk 2 beschrijft longitudinaal de klinische verschijnselen bij 25 
"sporadische" en 15 "familiaire" patiënten met selectieve IgA deficiëntie. 
Er werden geen duidelijke verschillen gevonden tussen "sporadische" en 
"familiaire" patiënten. In beide groepen had de meerderheid van de 
patiënten recidiverende luchtweginfecties, met name recidiverende otitis 
media. Atopische klachten werden ook frequent gevonden, en kwamen 
vaker voor in de "sporadische" groep. Er bestond geen duidelijke 
correlatie tussen de hoogte van de serum IgE concentraties en het 
voorkomen van atopische klachten. Chromosomale afwijkingen (ring 18 
en ring 22) werden alleen gevonden bij kinderen met selectieve IgA 
deficiëntie die tevens mentaal geretardeerd waren. Het tegelijk 
voorkomen van IgG subklasse deficiënties werd in beide groepen slechts 
bij enkele patiënten aangetoond. In beide groepen bleken de 
longitudinale serum IgG concentraties significant verhoogd te zijn, 
waarschijnlijk als gevolg van het verhoogde aantal infecties. Anti-lgA 
antistoffen waren aantoonbaar in 4 patiënten, 3 van hen hadden een 
moeder met IgA deficiëntie en circulerende klasse-specifieke anti-lgA 
antistoffen. Alle 4 patiënten hadden tevens een lgG4-lgE deficiëntie. 
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Hoofdstuk 3 beschrijft het pokeweed mitogeen-gestimuleerde 
celkweeksysteem voor in vitro Immunoglobuline productie dat in dit 
proefschrift gebruikt werd om de cellulaire basis van selectieve IgA 
deficiëntie te bestuderen. Door de in vitro Immunoglobuline producties in 
gemengde celkweken van non-T en Τ cel fracties van patiënten en 
gezonde controles statistisch met elkaar te vergelijken was het mogelijk 
om een defect in В cel functie, excessieve Τ suppressor functie en 
verminderde Τ helper cel functie te onderscheiden. De gebruikte 
methoden en de statistische berekeningen worden beschreven. 
Hoofdstuk 4 beschrijft de resultaten van in vitro Immunoglobuline 
productie in 22 kinderen met selectieve IgA deficiëntie (14 "sporadische" 
en 8 "familiaire") in relatie met de klinische verschijnselen. Alle patiënten 
op één na hadden een defect voor in vitro IgA productie. In de 
gemengde celkweken bleek dat alle patiënten op één na п В cel 
defect hadden voor in vitro IgA productie. Als belangrijkste oorzaak voor 
selectieve IgA deficiëntie op cellulair niveau werd in deze studie dus een 
IgA В cel defect gevonden. In 12 patiënten werden tevens Τ cel 
regulatie- stoornissen gevonden. Drie hadden IgA-specifieke excessieve 
Τ suppressor functie. Een verminderde Τ helper aktiviteit was in 4 
patiënten aantoonbaar voor in vitro IgA productie, terwijl 5 patiënten een 
verminderde Τ helperfunctie toonden voor zowel in vitro IgA als IgM 
productie. Er werden geen duidelijke verschillen waargenomen tussen 
"sporadische" en "familiaire" patiënten. Het is niet duidelijk welke 
betekenis aan de additionele Τ cel regulatiestoornissen moet worden 
toegekend in de Pathogenese van selectieve IgA deficiëntie. Er werd 
geen verschil gevonden in klinische verschijnselen tussen patiënten met 
uitsluitend een В cel defect en patiënten met een В cel defect en tevens 
IgA-specifieke Τ cel regulatiestoornissen. Het viel op dat bijna alle 
patiënten met infecties van ernstiger aard, dan wel klachten anders dan 
recidiverende luchtweginfecties of atopie, tevens een afwijkende in vitro 
IgM productie hadden. Misschien hebben deze patiënten een 
uitgebreidere immuundeficiëntie in die zin dat zij in de richting gaan van 
een common variable immunodeficiency. Deze hypothese zou een 
verklaring kunnen vormen voor de heterogeniteit die waargenomen wordt 
in patiënten met selectieve IgA deficiëntie. 
Hoofdstuk 5 beschrijft de resultaten van de in vitro Immunoglobuline 
productie experimenten in 4 "familiaire" kinderen met selectieve IgA 
deficiëntie. Zij behoren tot twee families waarin de moeders IgA deficiënt 
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zijn en circulerende anti-lgA antistoffen hebben. In één van de families is 
transplacentaire passage van maternale anti-lgA antistoffen aangetoond. 
In de literatuur is gesuggereerd dat in sommige patiënten met selectieve 
IgA deficiëntie het IgA systeem in de perinatale periode beïnvloed is 
door maternale anti-lgA antistoffen, hoewel het mechanisme onduidelijk 
bleef. De gemengde celkweken in onze patiënten lieten zien dat alle vier 
de kinderen een IgA В cel defect hadden gecombineerd met IgA-
specifieke excessieve Τ suppressor functie. Wij zijn van mening dat de 
passage van anti-lgA antistoffen in de kinderen excessieve Τ suppressor 
aktiviteit heeft geïnduceerd die uiteindelijk de IgA В cel functie aantast. 
Dit laatste Is niet beperkt tot de perinatale periode daar één van de 
kinderen pas IgA deficiënt werd na de leeftijd van een jaar. Drie van de 
kinderen ontwikkelden anti-lgA antistoffen op verschillende leeftijden 
doch vóór de puberteit. 
Hoofdstuk 6 beschrijft 3 patiënten met juveniele chronische arthritis bij 
wie een duidelijke daling ontstond van de serum IgA concentraties na 
behandeling met aurothioglucose. Eén van hen ontwikkelde een 
persisterende "echte" selectieve IgA deficiëntie en wordt nog steeds 
behandeld met goud. In de tweede patient bleven de serum IgA 
concentraties ver onder de normaalwaarden na staken van de 
goudinjecties. In de derde patient herstelden de serum IgA concentraties 
zich tot de waarden gemeten voor de start van de behandeling. 
Toxische bijwerkingen van goud werden niet waargenomen, en er was 
geen toename van infecties. In vitro Immunoglobuline productie 
experimenten lieten zien dat alle drie patiënten een verminderde IgA В 
cel functie hadden. Tenminste één van de twee patiënten die nog met 
goud behandeld werden op het tijdstip van de celkweken had ook een 
verminderde IgM В celfunctie, hoewel in beiden de serum IgM 
concentraties normaal waren. Uit de in vitro experimenten kon 
geconcludeerd worden dat aurothioglucose kan interfereren met in vitro 
В cel functie. In sommige patiënten kan hierdoor een daling in 
Immunoglobuline concentraties ontstaan, met name van IgA. In 
tegenstelling tot de meeste patiënten met primaire selectieve IgA 
deficiëntie veroorzaakte dit in onze 3 patiënten geen symptomen. 
Hoofdstuk 7 toont de longitudinale Immunoglobuline concentraties in 36 
kinderen met selectieve IgA deficiëntie (25 "sporadisch" en 11 "familiair"). 
In de meeste kinderen bleven de serum en speeksel IgA concentraties 
onder de 2 mg/l. In 8 kinderen werden forse schommelingen 
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waargenomen van de serum IgA concentraties, maar allen bleven IgA 
deficiënt. Vijf kinderen ontwikkelden op verschillende leeftijden serum IgA 
concentraties boven 50 mg/l en IgA was aantoonbaar In speeksel. Zij 
zouden beschouwd kunnen worden als transient IgA deficiënt, echter 
geen van hen heeft tot nu toe de ondergrens van de normaalwaarden 
voor IgA bereikt. De serum IgG subklasse concentraties waren, zelfs al 
op jonge leeftijd, bij de meeste kinderen vrij hoog. Er werden geen 
duidelijke verschillen in immunoglobuline concentraties waargenomen 
tussen de twee groepen behalve een associatie tussen enerzijds IgD 
deficiëntie en serum IgA onder 2 mg/l en anderzijds tussen IgD boven 1 
IU/ml en serum IgA boven 2 mg/l, hetgeen statistisch significant was in 
de "sporadische" groep maar niet in de "familiaire" groep. Dit zou 
kunnen wijzen op een immunoregulatoire rol van IgD in het proces van 
IgA В cel differentiatie. 
Hoofdstuk 8 bestaat tenslotte uit een algemene bespreking van de 
klinische en immunologische bevindingen in de twee groepen patiënten 
met selectieve IgA deficiëntie, gevolgd door enkele suggesties voor 
toekomstig onderzoek. 
Concluderend bleek dat er nauwelijks verschillen aangetoond 
kunnen worden tussen "sporadische" en "familiaire" patiënten. De 
heterogeniteit van selectieve IgA deficiëntie kan aldus niet verklaard 
worden. Anti-lgA antistoffen werden gevonden bij 6 patiënten (4 kinderen 
en 2 moeders) en allen hadden tevens een lgG4-lgE deficiëntie. 
Ontwikkeling van anti-lgA antistoffen vóór de puberteit werd alleen 
gevonden bij de kinderen van moeders met IgA deficiëntie en anti-lgA 
antistoffen. Op grond van de bevindingen in dit proefschrift is selectieve 
IgA deficiëntie gebaseerd op (regulatoire) stoornissen in В cel 
differentiatie. In sommige patiënten is dit beperkt tot IgA, in anderen 
bestaan meer uitgebreide stoornissen die ook andere immunoglobulines 
kunnen betreffen. De veronderstelling dat selectieve IgA deficiëntie één 
zijde vormt van een breder spectrum van stoornissen in 
immunoglobuline synthese met aan de andere kant common variable 
immunodeficiency, zou een redelijke verklaring kunnen zijn voor de 
heterogeniteit van patiënten met selectieve IgA deficiëntie. 
140 
DANKWOORD 
Dit proefschrift is tot stand gekomen dankzij de hulp van velen. 
Op de eerste plaats wil ik de patiënten en hun ouders bedanken voor 
hun medewerking aan de in vitro experimenten. De controles bedank ik 
voor hun bereidwilligheid om belangeloos een niet geringe hoeveelheid 
bloed af te staan voor mijn onderzoek. 
Prof.Dr. G.B.A. Stoellnga bedank ik voor mijn opleiding tot kinderarts en 
de mogelijkheid om tijdens deze opleiding het onderzoek te verrichten 
dat de basis vormt van dit proefschrift. 
Dr. C.M.R. Weemaes, beste Corry, bedankt voor je voortdurende steun 
en begeleiding tijdens alle fasen van het onderzoek. Ik heb veel geleerd 
van jouw visie op klinische immunologie bij kinderen. 
Dr. J.A.J.M. Bakkeren, beste Jan, bedankt voor de gastvrijheid waarmee 
ik ontvangen ben op het Cel en Weefselkweeklaboratorium. Ook daarna 
was je altijd bereid om te blijven meedenken, zowel inhoudelijk als over 
de punten en de komma's. 
Dr. P.J.J. van Munster, beste Piet, bedankt voor je hulp п medewerking 
in de beginfase, en de interesse die je, ook na je pensionering, had 
voor de voortgang van het onderzoek. 
F.CA. van den Brandt, beste Frans, jou wil ik bedanken voor de 
spoedcursus in het verrichten van celkweken en je steun tijdens het in 
de praktijk brengen van die kennis. De kweken van hoofdstuk 5 en 6 
zijn grotendeels door jou gedaan. Samen met Harriet van Lith en 
Marianne Broedelet heb je ook het tijdrovende en veel ervaring 
vereisende immunofluorescentie-werk verricht. 
T.G.P.M. van Lith, beste Theo, bedankt voor de energie om m.b.v. ELISA 
in enkele duizenden buisjes de in vitro Immunoglobuline productie te 
meten, en voor je zorgvuldige verslaglegging daarvan. 
Dr. R. de Graaf en Ing. J. Mulder, beste Ruurd en Jan, bedankt voor de 
statistische bewerking van de onderzoeksgegevens. 
Cees Nicolasen en Joop van Dijk wil ik bedanken voor de tekeningen. 
Marike van Groen, Annelies de Reus en Irma Beckers ben ik dankbaar 
voor de ruimte die zij mij boden voor het printen van versie na versie. 
De collega's in Nijmegen en Rotterdam gaven mij af en toe de 
broodnodige gelegenheid om voltijds aan dit proefschrift te kunnen 
werken, waarvoor mijn dank. 
Mijn ouders, bedankt voor alles. 
Paul en Frank, hopelijk kunnen we binnenkort vaker samen "pjoeteren". 
Elly, woorden schieten te kort, zonder jou was dit niet mogelijk geweest. 
141 

CURRICULUM VITAE 
De auteur van dit proefschrift werd op 12 maart 1958 geboren te 
Tilburg. Hij behaalde in 1976 het Atheneum В diploma aan het 
Pauluslyceum te Tilburg. Vanaf 1976 studeerde hij Geneeskunde aan de 
Katholieke Universiteit te Nijmegen, en behaalde op 8 juli 1983 het arts­
examen. Van september 1983 tot november 1984 was hij werkzaam als 
onderdeelsarts ter vervulling van de militaire dienstplicht. 
De opleiding tot kinderarts werd aangevangen in november 1984 in 
het Radboudziekenhuis te Nijmegen (Opleider: Prof.Dr. G.B.A. Stoelinga). 
De opleiding werd tijdelijk onderbroken van november 1985 tot mei 
1986. In die periode werd het hem dankzij een subsidie van de 
Facultaire arts-assistentenpool mogelijk gemaakt om onder leiding van 
Dr. C.M.R. Weemaes de basis te leggen van het onderzoek dat 
uiteindelijk geleid heeft tot dit proefschrift. Hij was toen werkzaam op het 
Cel en Weefselkweek laboratorium (Hoofd: Dr. J.A.J.M. Bakkeren) van 
het Laboratorium Kindergeneeskunde en Chirurgie (voormalig Hoofd: Dr. 
P.J.J. van Munster). 
De opleiding werd in mei 1986 voortgezet en hij werd op 1 april 
1989 ingeschreven als kinderarts in het specialistenregister. Sindsdien is 
hij werkzaam op de afdeling Kindergeneeskunde (Hoofd: Prof.Dr. H.K.A. 
Visser) van het Sophia Kinderziekenhuis te Rotterdam. 
Hij is gehuwd met Elly Reijgersberg en vader van Paul en Frank. 
143 
Dit proefschrift Is geschreven op een XT-PC met behulp van WP 5.0. Het gebruikte 
lettertype is Swiss Roman 12pt voor de tekst, Swiss Roman 10pt voor de tabellen en de 
referenties, en Swiss Italie 10pt voor de figuren. De regelafstand is 1,15. De marges zijn 
2,54 cm rondom. Het is geprint op een laserprinter en daarna door de drukker 80% 
verkleind. 
Haveka B.V. Alblasserdam 
Г 
STELLINGEN 
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SELECTIVE IgA DEFICIENCY IN CHILDHOOD 
Clinical manifestations and In vitro experiments 
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door 
PETER C.J. DE LAAT 
1. Selectieve IgA deficiëntie is op de kinderleeftijd vooral geassocieerd met 
recidiverende luchtweginfecties, in het bijzonder otitis media. 
(dit proefschrift) 
2. Atopische klachten worden frequent aangetroffen bij patiënten met selectieve 
IgA deficiëntie maar tonen dan vaak geen goede correlatie met de hoogte van 
de serum IgE concentraties. 
(dit proefschrift) 
3. Selectieve IgA deficiëntie wordt veroorzaakt door een regulatiestoornis in het 
proces van В cel differentiatie tot rijpe IgA secreterende plasmacel. 
(dit proefschrift) 
4. Het feit dat een aantal patiënten immunologisch gesitueerd moet worden tussen 
selectieve IgA deficiëntie en common variable immunodeficiency kan de 
heterogeniteit van patiënten met selectieve IgA deficiëntie verklaren. 
(dit proefschrift) 
5. Transplacentaire passage van anti-lgA antistoffen van moeder naar kind kan de 
oorzaak zijn van IgA deficiëntie bij het kind. Bij deze kinderen ontstaan dan 
anti-lgA antistoffen vóór de puberteit. 
(dit proefschrift) 
6. Medium-chain acylCoA-dehydrogenasedeficiëntie (MCAD) is in N-W Europa één 
van de meest voorkomende "inborn errors" van de beta-oxidatie van vetzuren 
en kan verantwoordelijk zijn voor SIDS en Reye-like syndrome op de vroege 
kinderleeftijd. In families met onbegrepen onverwachte dood dient daarom 
MCAD bij siblings van SIDS te worden uitgesloten. 
(Blakemore et el. Lancet 1991;337:298-9.) 
7. De RAAS-antagonerende, vochtmobiliserende en longvaatverwijdende 
eigenschappen van het Atrium-Natriuretische Peptide (ANP), en de positieve 
correlatie tussen verhoogde plasma ANP concentraties en de mate van 
ductusflow bij de pasgeborene, doen een belangrijke rol van dit hormoon 
vermoeden bij de aanpassing van de foetale circulatie aan het extra-uteriene 
bestaan. 
(Semmekrot et al. Biol Neonate (in press)) 
8. Bij de combinatie van neurologische uitvalsverschijnselen en microcytaire 
anaemie dient ook in Nederland nog steeds gedacht te worden aan een 
loodintoxicatie. 
9. De toenemende subspecialisatie in de kindergeneeskunde in de academische 
kinderklinieken houdt het gevaar in dat de "integrale" kindergeneeskundige zorg 
tekort gaat schieten. Dit kan slechts voorkomen worden door een duidelijke 
plaats te geven aan academische kinderartsen die functioneren als generalist. 
10. De voorkeur van de gemiddelde Nederlander voor het kiezen van een 
"middenweg" weerspiegelt zich ook maar al te vaak in het weggedrag op 
autowegen met meer dan twee rijstroken. 
11. Een deel van het speurwerk van een aankomend promovendus zou kunnen 
vervallen indien achterin elk proefschrift de technische gegevens van de lay-
out zouden staan. 



